{"study_id": 484, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the relationship between noninvasively measured AGEs score at the fingertip and the prognosis of major adverse cardiovascular and cerebrovascular events (MACCE) in patients with cardiovascular disease (CVD).", "results_summary": "The study found that higher AGEs scores were significantly associated with a greater incidence of MACCE (27.1% vs. 10.5%) and identified AGEs score as an independent risk factor for MACCE, with a cutoff value of 0.51 providing moderate predictive accuracy (AUC 0.642).", "population_specificity": "191 outpatients with cardiovascular disease (CVD).", "effective_dosage": "Not specified", "study_duration": "30 months (follow-up period)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:26.386552+00:00"}
{"study_id": 485, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the role of the MGO-AGEs-RAGE pathway in diabetes-associated bladder dysfunction in diabetic ob/ob mice and the effects of the AGE breaker alagebrium (ALT-711).", "results_summary": "Diabetic ob/ob mice exhibited elevated levels of MGO, AGEs, RAGE, and collagen in bladder tissues, along with increased void volume, which were significantly reduced by ALT-711 treatment. ALT-711 also normalized void volume and increased spot number, indicating improved bladder function.", "population_specificity": "Diabetic male and female ob/ob mice compared with wild-type lean mice.", "effective_dosage": "1 mg/kg in drinking water.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:26.621805+00:00"}
{"study_id": 491, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the potential of AGE breakers to target age-related changes in the ovarian cancer microenvironment, with the long-term goal of improving therapy response in older patients.", "results_summary": "The study found that AGE breakers could alter omental collagen structure and modulate the peritoneal immune landscape, suggesting their potential use in ovarian cancer treatment.", "population_specificity": "Women over 60 with ovarian cancer.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:29.771223+00:00"}
{"study_id": 487, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether catalpol could inhibit AGEs-induced angiogenesis and inflammation in glomerular endothelial cells and macrophages, potentially preventing diabetic nephropathy progression.", "results_summary": "Catalpol effectively blocked AGEs-induced proliferation of cells, reduced pro-angiogenic factors, and inhibited the HIF-1\u03b1/galectin-3 pathway, demonstrating anti-angiogenic and anti-inflammatory effects. Overexpression of galectin-3 reversed these effects, confirming its role in AGEs-mediated damage.", "population_specificity": "Mouse glomerular endothelial cells (mGECs), RAW 264.7 macrophages, and a rat model of diabetic nephropathy.", "effective_dosage": "Catalpol (10 \u00b5mol/L in vitro, 100 mg/kg in vivo), AGEs (50 \u00b5g/mL in vitro).", "study_duration": "12 weeks (in vivo).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:30.065081+00:00"}
{"study_id": 490, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate whether soluble RAGE (sRAGE) and HMGB1 levels could predict the development of pulmonary complications (ILD and PAH) in systemic sclerosis (SSc) patients.", "results_summary": "Higher baseline sRAGE levels were independently associated with PAH and predicted its development and related mortality, while lower sRAGE levels were linked to ILD. HMGB1 levels showed no significant differences between groups.", "population_specificity": "188 systemic sclerosis (SSc) patients followed for pulmonary complications.", "effective_dosage": "Not specified (measured serum levels via ELISA).", "study_duration": "Median follow-up of 50 months (range 25-81).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:30.252641+00:00"}
{"study_id": 486, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the anti-aging ability of Fenugreek seeds extract (FgSE) by assessing its inhibition of Advanced Glycation End Products (AGEs) and its effects on cognition in a high fructose diet-induced glycation model.", "results_summary": "FgSE inhibited AGEs formation and preserved BSA's secondary structure in vitro. In vivo, FgSE improved cognition and reduced CML levels in serum and hippocampus, suggesting it prevents glycation-induced memory decline by trapping reactive carbonyl intermediates.", "population_specificity": "In vitro model (Bovine serum albumin/fructose) and in vivo model (High Fructose Diet-induced glycation in animals).", "effective_dosage": "In vitro: 0.1, 0.5, and 1 mg/ml; in vivo: 10, 25, and 50 mg/kg.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:30.253915+00:00"}
{"study_id": 488, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to assess the concentration of advanced glycation end-products (AGE) in the skin autofluorescence (SAF) exam in patients with select rheumatic diseases and determine its association with depression.", "results_summary": "The study found that patients with rheumatic diseases and depression had significantly higher mean SAF (2.8 \u00b1 0.4) compared to those without depression (2.2 \u00b1 0.5), suggesting that depression may influence AGE concentration in the skin. Evaluating AGE levels could help identify patients at risk of developing depression.", "population_specificity": "139 patients with rheumatic diseases (43 with RA, 31 with PsA, 27 with SLE, and 38 with SSc).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:30.426256+00:00"}
{"study_id": 489, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the role of dietary advanced glycation end products (AGEs) in contributing to insulin resistance (IR) and their potential impact on chronic diseases.", "results_summary": "The study found that reducing dietary AGE intake is associated with improved insulin resistance in various disease conditions, supported by evidence from small clinical trials and animal studies. Simple culinary technique changes were noted as a feasible intervention to reduce AGE content in foods.", "population_specificity": "Aging individuals and those with chronic nontransmissible diseases.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:30.899080+00:00"}
{"study_id": 492, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 65, "study_goal": "The researchers aimed to investigate the relationship between HMGB1, sRAGE, and depressive symptoms in severely depressed patients undergoing electroconvulsive therapy (ECT).", "results_summary": "The study found no significant differences in HMGB1 and sRAGE concentrations between depressed patients and healthy subjects, nor any changes after ECT. There was also no correlation between these biomarkers and depressive symptoms.", "population_specificity": "25 patients with severe major depressive disorder (11 males, 14 females) requiring ECT, and 25 age- and gender-matched healthy subjects.", "effective_dosage": "Not specified", "study_duration": "Duration of ECT course not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:35.662342+00:00"}
{"study_id": 496, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the effects of cereal polyphenols in inhibiting Advanced Glycation End Products (AGEs) and their potential role in preventing and alleviating type 2 diabetes.", "results_summary": "The study found that AGEs contribute to oxidative stress, inflammation, and gut microbiota imbalance, while cereal polyphenols can inhibit AGE formation and mitigate these effects, offering a nonpharmacologic approach to diabetes management.", "population_specificity": "Not specified (review article)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:37.779351+00:00"}
{"study_id": 495, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of AGEs in renal function decline in the elderly and the protective effects of resveratrol compared to aminoguanidine.", "results_summary": "The study found that AGEs significantly increased renal dysfunction markers in aging mice, which were reversed by treatment with aminoguanidine or resveratrol, suggesting resveratrol's potential to alleviate AGEs-related renal dysfunction.", "population_specificity": "D-galactose-induced aging mouse model", "effective_dosage": "Not specified", "study_duration": "Eight weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:37.821178+00:00"}
{"study_id": 498, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 35, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the relationship between dietary and serum advanced glycation end-products (AGEs) with inflammatory and oxidative stress biomarkers in breast cancer patients.", "results_summary": "The study found limited correlation between dietary AGEs (dCML) and serum inflammation/oxidative stress biomarkers, except for a weak positive correlation with malondialdehyde at one time point. HER2- subtype showed higher AGEs and biomarker levels compared to HER2+.", "population_specificity": "32 women with breast cancer and 32 age- and BMI-matched healthy women.", "effective_dosage": "Not specified", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:38.208472+00:00"}
{"study_id": 497, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to investigate the role of RAGE (receptor for advanced glycation end-products) in blood-brain barrier integrity and its mechanisms in postoperative delirium-like behaviors.", "results_summary": "The study found that anesthesia with surgery disrupted BBB integrity by reducing tight junction proteins (occludin and claudin 5) and increasing MMP2/9 levels, leading to POD-like behavior. The RAGE antagonist FPS-ZM1 reversed these effects, suggesting RAGE signaling as a potential therapeutic target for POD prevention.", "population_specificity": "Aged mice", "effective_dosage": "2.5% sevoflurane anesthesia (duration not specified for dosage frequency)", "study_duration": "Not explicitly stated (intervention involved anesthesia and exploratory laparotomy)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:39.299435+00:00"}
{"study_id": 499, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether inhibiting AGE formation or AGE-ECM cross-linking enhances experimental abdominal aortic aneurysms (AAAs) in diabetic mice.", "results_summary": "Inhibiting AGE formation (aminoguanidine) or AGE-ECM cross-linking (alagebrium) enhanced AAA enlargement in diabetic mice, promoting elastin degradation and other pathological changes, supporting the hypothesis that AGEs attenuate AAAs in diabetes.", "population_specificity": "Male C57BL/6J mice with induced diabetes and experimental AAAs.", "effective_dosage": "Aminoguanidine (200 mg/kg daily), alagebrium (20 mg/kg daily).", "study_duration": "Daily administration from the last day following streptozotocin injection (exact duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:40.569712+00:00"}
{"study_id": 500, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate skin AGE deposition, serum CML, and serum sRAGE levels in hypothyroid and hyperthyroid patients to understand the association between thyroid dysfunction and AGE accumulation.", "results_summary": "The study found increased skin AGE deposition (SAF) in both hypo- and hyperthyroid patients compared to euthyroid controls, with higher serum CML levels in hyperthyroid patients. No significant differences in sRAGE levels were observed between groups.", "population_specificity": "103 hypothyroid patients, 50 hyperthyroid patients, and 50 euthyroid controls (all newly diagnosed and without diabetes mellitus).", "effective_dosage": "Not specified", "study_duration": "Not specified (cross-sectional study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:44.406900+00:00"}
{"study_id": 101063, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to understand how glycation and other post-translational modifications affect \u03b1-crystallin's function and its role in cataract formation, particularly in diabetics.", "results_summary": "The study found that advanced glycation end-products (AGEs) impair \u03b1-crystallin's chaperone function by cross-linking molecules, leading to structural changes and reduced ability to prevent protein aggregation, which increases cataract risk in diabetics.", "population_specificity": "Diabetics and individuals with metabolic disorders (implied).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:45.688592+00:00"}
{"study_id": 101064, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to synthesize current findings on RAGE's involvement in the pathophysiology of skin diseases and examine RAGE-modulating treatments in dermatological contexts.", "results_summary": "The review highlights RAGE's roles in inflammatory signaling, tissue remodeling, and skin cancer progression in conditions like psoriasis, atopic dermatitis, and lichen planus, and discusses potential therapeutic options targeting RAGE.", "population_specificity": "Not specified (review of existing literature on skin diseases)", "effective_dosage": "Not available", "study_duration": "Not applicable (review study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:45.922537+00:00"}
{"study_id": 493, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether blocking RAGE signaling with soluble RAGE (sRAGE) could attenuate renal fibrosis in chronic kidney disease models.", "results_summary": "sRAGE treatment reduced fibrotic markers (fibronectin, type I collagen, \u03b1-smooth muscle actin) and suppressed MAPK and NF-\u03baB pathways in both in vitro and in vivo models of renal fibrosis. Masson's trichrome staining confirmed sRAGE's anti-fibrotic effects in UUO rats.", "population_specificity": "NRK-52E cells (in vitro) and Sprague-Dawley rats with unilateral ureteral obstruction (in vivo).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:46.107835+00:00"}
{"study_id": 101065, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the effects of Probucol, a lipid-lowering and antioxidant drug, on plasma A\u03b2 transport and its potential implications for Alzheimer's disease.", "results_summary": "Probucol significantly increased plasma A\u03b2 levels and sRAGE, suggesting enhanced A\u03b2 transport from the brain to peripheral blood, while also improving lipid profiles. The study concluded that Probucol could be beneficial in modulating A\u03b2-related pathways.", "population_specificity": "108 hyperlipidemic patients with normal cognition (53.7% women, mean age 58.4 years).", "effective_dosage": "1000 mg daily", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:46.566873+00:00"}
{"study_id": 494, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the effects of Advanced Glycation End Products (AGEs) on chronic kidney disease (CKD) progression and their correlation with CAPN6.", "results_summary": "AGEs were found to inhibit cell proliferation and glycolysis while accelerating apoptosis in HK-2 cells. CAPN6 knockdown reversed these effects, and overexpressed CAPN6 mimicked AGEs' detrimental impact.", "population_specificity": "Patients with CKD stages 3, 4, and 5, and HK-2 cells (a human kidney cell line).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:46.768938+00:00"}
{"study_id": 101066, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to review the role of HMGB1 in disease onset and progression, its druggability, and future research directions.", "results_summary": "The abstract highlights HMGB1's dual functionality in cellular processes and disease progression but notes gaps in understanding its mechanistic pathways. It also discusses potential clinical benefits of HMGB1-targeting biologics.", "population_specificity": "Not specified (review article)", "effective_dosage": "Not mentioned", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:46.976276+00:00"}
{"study_id": 101067, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in neurodegenerative diseases and potential therapeutic strategies targeting AGEs or the AGE-RAGE axis.", "results_summary": "The study found that AGEs contribute to neurodegenerative disorders by promoting protein cross-linking, aggregation, and activating neuroinflammatory and oxidative stress pathways. Therapeutic efforts targeting AGE production or the AGE-RAGE axis show promise in slowing disease progression in conditions like Alzheimer's, Parkinson's, and Huntington's diseases.", "population_specificity": "Not specified (general focus on neurodegenerative diseases).", "effective_dosage": "Not available.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:49.199111+00:00"}
{"study_id": 101068, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to elucidate the molecular mechanism of Wensan tincture (WST) in treating pulmonary nodules, focusing on pathways involving Advanced Glycation End Products (AGEs) and their receptor signaling.", "results_summary": "The study identified 62 active ingredients in WST targeting key pathways, including AGEs and their receptor signaling, with quercetin showing strong binding affinity to mitogen-activated protein kinase-3. WST components demonstrated potential as drug candidates for pulmonary nodules.", "population_specificity": "Not specified (in silico study using databases and molecular docking).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:53.093569+00:00"}
{"study_id": 101069, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the pathological mechanisms influenced by RAGE and assess its potential as a biomarker and therapeutic target.", "results_summary": "The study highlights the role of RAGE-ligand interactions in chronic inflammation and oxidative damage linked to various diseases, but notes that RAGE has not yet been incorporated into mainstream treatment for any condition.", "population_specificity": "Not specified (review of existing research, including knockout animals and human trials).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:54.042050+00:00"}
{"study_id": 101075, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the predictive capacity of biomarkers, including sRAGE, for clinical pulmonary oedema in severe malaria patients.", "results_summary": "The study found that sRAGE levels were elevated in severe malaria patients compared to healthy controls but could not predict clinical pulmonary oedema. Biomarker levels correlated with disease severity markers like PfHRP2.", "population_specificity": "Patients with severe falciparum malaria in Bangladesh.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:54.866874+00:00"}
{"study_id": 101073, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the pathogenic role of the AGEs-RAGE-oxidative stress axis in diabetes and evaluate the therapeutic potential of natural polysaccharides in managing diabetes and its complications.", "results_summary": "The study found that natural polysaccharides can inhibit AGE formation, regulate RAGE expression, and modulate the AGEs-RAGE-oxidative stress axis, suggesting their potential in diabetes management. The paper reviews these mechanisms and highlights the therapeutic promise of natural polysaccharides.", "population_specificity": "Not specified (general diabetes-related research)", "effective_dosage": "Not provided", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:54.989239+00:00"}
{"study_id": 101071, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of advanced glycation end products (AGEs) in Alzheimer's disease (AD) pathology and the potential therapeutic benefits of DPP IV inhibitors in targeting AD-like pathology.", "results_summary": "The study found that DPP IV inhibitors significantly reduce A\u03b2 oligomerization, phosphorylated tau (p-tau), oxidative stress, and inflammatory markers, suggesting potential efficacy in managing AD-like pathology. However, clinical trials are needed to validate these preclinical findings.", "population_specificity": "Preclinical experimental settings (not specified if human or animal models).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:55.053445+00:00"}
{"study_id": 101070, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to examine the role of Advanced Glycation End Products (AGEs) in the etiology, mechanisms, and treatment of diabetic nephropathy.", "results_summary": "The study found that AGEs, along with other factors like PKC activation and RAAS overexpression, contribute to glomerular hyperfiltration, hypertrophy, and renal fibrosis in diabetic nephropathy. Current treatments focus on glycemic control, hypertension management, and RAAS suppression, but AGEs remain a key pathological factor.", "population_specificity": "Individuals with diabetes, particularly those at risk for or diagnosed with diabetic nephropathy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:55.167703+00:00"}
{"study_id": 101074, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the relationship between chronic hyperglycemia, oxidative stress, and cellular mechanisms underlying diabetic kidney disease (DKD), focusing on Advanced Glycation End Products (AGEs) as potential contributors to disease progression.", "results_summary": "The review highlights the interconnection between hyperglycemia, oxidative stress, and cellular mechanisms leading to organelle dysfunction, fibrosis, and podocyte impairment in DKD, suggesting AGEs as a key factor in disease progression. It emphasizes the need for further research to identify druggable targets for DKD treatment.", "population_specificity": "Diabetic kidney disease (DKD) patients, primarily based on observational studies and reviews.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:55.991294+00:00"}
{"study_id": 101076, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of advanced glycation end-products (AGEs) in retinal homeostasis, aging, and disease, particularly their association with metabolic dysregulation.", "results_summary": "The study identified elevated levels of AGEs in the aging and diseased retina, linking them to metabolic dysregulation and suggesting their potential role in age-related macular degeneration (AMD). It also highlighted the broader impact of AGEs on glucose, mitochondrial, lipid, and amino acid metabolism in non-retinal tissues.", "population_specificity": "Aging and diseased retina (e.g., age-related macular degeneration patients).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:57.392649+00:00"}
{"study_id": 101079, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of RAGE-mediated inflammation in rotator cuff injury (RCI) and evaluate novel therapeutic factors like PKCs, TIRAP, and DIAPH1 for improving clinical outcomes.", "results_summary": "The study highlighted RAGE's crucial role in inflammation during RCI and discussed potential therapeutic targets, but noted that further investigation is needed to confirm their clinical benefits.", "population_specificity": "Individuals with rotator cuff injury (RCI).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:01.260091+00:00"}
{"study_id": 101077, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers investigated the relationship between GDF-15 levels and PCOS, including the effect of metformin on GDF-15 and potential biologic pathways involving Advanced Glycation End Products (AGE/RAGE).", "results_summary": "The study found that GDF-15 levels were higher in women with PCOS and further increased with metformin treatment. GDF-15 was linked to biologic pathways involving AGE/RAGE, oxidative stress, and insulin-related mechanisms.", "population_specificity": "35 women with PCOS and 32 controls; additional analysis included 22 women with PCOS (7 treated with metformin, 15 placebo).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:01.440918+00:00"}
{"study_id": 101082, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to highlight the role of Advanced Glycation End Products (AGEs) in the complex pathogenesis of Metabolic dysfunction-associated steatotic liver disease (MASLD).", "results_summary": "The abstract mentions AGEs as part of an intricate network contributing to MASLD's pathogenesis but does not provide specific findings on their effects.", "population_specificity": "Not specified (broad focus on MASLD and metabolic dysfunction).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:02.014086+00:00"}
{"study_id": 101083, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore and validate the predictive value of clinical parameters combined with plasma biomarkers for ARDS in high-risk SICU patients.", "results_summary": "The study identified 15 risk factors differentiating ARDS and non-ARDS patients, including IL-6, IL-8, and LIPS, and developed a predictive nomogram.", "population_specificity": "High-risk patients in a surgical intensive care unit (SICU).", "effective_dosage": "Not available", "study_duration": "Data collected from admission up to 7 days for non-ARDS patients and until 1 day post-ARDS onset for ARDS patients.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:03.226836+00:00"}
{"study_id": 101084, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the predictive value of advanced glycation end products (AGEs) and extracellular vesicles (EVs) for systolic and diastolic dysfunction progression in heart failure patients with mildly-reduced ejection fraction (HFmrEF).", "results_summary": "Increased leukocyte EV concentrations were associated with a 4.7-fold higher odds of systolic dysfunction progression, while skin AGE levels and other EV subtypes showed no association with dysfunction progression. Leukocyte EVs predicted systolic dysfunction progression with 75.0% sensitivity and 58.3% specificity.", "population_specificity": "74 patients with heart failure and mildly-reduced ejection fraction (HFmrEF).", "effective_dosage": "Not specified", "study_duration": "6.5 months follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:03.338500+00:00"}
{"study_id": 101080, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the existing knowledge on Echinacoside (ECH), including its pharmacological activities, structure-activity relationship, and potential mechanisms of action, particularly its interaction with receptors like RAGE (receptor for advanced glycation end products).", "results_summary": "The study highlights ECH's diverse pharmacological activities, including anti-diabetic, anti-inflammatory, and anti-skin glycation effects, with in silico studies suggesting its binding to RAGE and other receptors to modulate these effects. The compound's multifaceted properties underscore its potential for clinical research, though more comprehensive studies are needed to fully understand its mechanisms.", "population_specificity": "Not specified (review of existing literature)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:03.397074+00:00"}
{"study_id": 101085, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to explore potential therapeutic targets, including the GLP-1-arginine-advanced glycation end products axis, for obesity-related asthma.", "results_summary": "The abstract suggests that advanced glycation end products are part of a potential therapeutic axis for obesity-related asthma, but human data are still lacking. Existing treatments like GLP-1 receptor agonists show promise but require further study.", "population_specificity": "Individuals with obesity-related asthma, including pediatric populations (though limited data available for youth).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:03.457353+00:00"}
{"study_id": 101086, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the potential role of HMGB-1 and its receptors (including RAGE) in the onset and progression of diabetes complications, focusing on inflammatory pathways.", "results_summary": "The study suggests that HMGB-1 and its receptors (RAGE and TLRs) are promising targets for antidiabetic interventions, with potential to ameliorate diabetes and its complications through anti-inflammatory approaches.", "population_specificity": "Not specified (review paper, not a clinical study)", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:04.736177+00:00"}
{"study_id": 101087, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to assess the association between consumption of ultra-processed foods, including Advanced Glycation End Products (AGEs), and the occurrence of allergic diseases in children.", "results_summary": "Childhood intake of AGEs was associated with the occurrence of allergic diseases, though not all studies showed consistent results. The study suggests a potential link but calls for more research to definitively establish causality.", "population_specificity": "Pediatric population (children)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:09.249608+00:00"}
{"study_id": 101088, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the mechanisms by which Advanced Glycation End Products (AGEs) contribute to diabetic nephropathy (DN) through SREBP activation and inflammation.", "results_summary": "The study found that AGEs promote renal lipid accumulation, inflammation, and fibrosis via RAGE signaling, SIRT-1 downregulation, and SCAP glycosylation, exacerbating DN progression. It also highlighted the link between glycation, SREBP pathway, and obesity-related DN.", "population_specificity": "Focused on mechanisms relevant to diabetic nephropathy, particularly in the context of obesity.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:10.061944+00:00"}
{"study_id": 101091, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of the RAGE/DIAPH1 signaling pathway in atherosclerosis and assess potential therapeutic strategies targeting this pathway.", "results_summary": "The study found that antagonism or deletion of RAGE/DIAPH1 signaling shows promise in mitigating accelerated atherosclerosis, particularly in diabetic and other cardiovascular disease contexts.", "population_specificity": "Non-diabetic and diabetic mice.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:10.552530+00:00"}
{"study_id": 101090, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to consolidate the characteristics of AGEs, their role in chronic diseases, and evaluate the clinical relevance of interventions targeting AGE accumulation.", "results_summary": "The study found that AGEs are potent diagnostic indicators and that early intervention with AGE cross-link breakers shows encouraging results in heart failure patients. AGEs disrupt biological processes and are linked to chronic diseases across various organ systems.", "population_specificity": "Heart failure patients (specific population mentioned in early intervention studies).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:11.212847+00:00"}
{"study_id": 101094, "supplement_id": 857, "safety_score": "30", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the formation, potential harm, and mitigation strategies of Advanced Glycation End Products (AGEs) in processed foods.", "results_summary": "The study highlights that AGEs are harmful compounds formed during food processing, linked to health risks, and discusses potential mitigation strategies to reduce their impact.", "population_specificity": "General human health (not specific to a demographic).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:11.422660+00:00"}
{"study_id": 101093, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of the CX3CL1-CX3CR1 signaling axis in diabetic encephalopathy (DE) and its potential as a therapeutic target by modulating neuroprotective or neurotoxic effects.", "results_summary": "The study discusses conflicting evidence on whether CX3CL1-CX3CR1 signaling is neuroprotective or neurotoxic in DE, suggesting that targeting this pathway could limit neuroinflammation. Tight glycemic control remains the optimal approach to prevent DE.", "population_specificity": "Individuals with diabetes mellitus, particularly those at risk for or experiencing diabetic encephalopathy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:12.542014+00:00"}
{"study_id": 101092, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the potential mechanism of Xianlinggubao formula (XLGB) in treating diabetic osteoporosis (DOP), focusing on its regulation of advanced glycation end products (AGEs) and osteoclast differentiation.", "results_summary": "The study found that XLGB may regulate AGEs formation and osteoclast differentiation, as well as angiogenesis and adipogenesis, to combat DOP. Molecular docking confirmed the credibility of predicted therapeutic targets, including AKT serine/threonine kinase 1, tumor necrosis factor, and Interleukin-6.", "population_specificity": "Not specified (in vitro or computational study, no human or animal population mentioned).", "effective_dosage": "Not provided", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:12.754953+00:00"}
{"study_id": 101095, "supplement_id": 857, "safety_score": "20", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the relationship between the AGE-RAGE pathway and brain aging, identifying affected molecules and potential intervention targets.", "results_summary": "The study found that AGEs accumulate in brain tissue, contributing to neurodegeneration and cognitive decline by promoting inflammation, oxidative stress, and protein aggregation. Reducing AGE deposition through pharmacological, dietary, or lifestyle interventions shows promise in mitigating cognitive decline.", "population_specificity": "General brain aging (not specified beyond this context).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:18.232010+00:00"}
{"study_id": 101096, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to explore the role and mechanisms of vitamin D3 in follicular development, including its effects on reducing oxidative stress and advanced glycation end-products (AGEs).", "results_summary": "Vitamin D3 was found to reduce oxidative stress and AGEs, mitigating inflammation's detrimental effects on follicular development. It also promoted oocyte and granulosa cell development, enhancing fertility outcomes.", "population_specificity": "Female reproduction, particularly follicular development and fertility.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:18.918843+00:00"}
{"study_id": 101089, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products in activating the NF-\u03baB signaling pathway and its contribution to cardiomyocyte pyroptosis in heart failure.", "results_summary": "The study found that Advanced Glycation End Products, along with other biological factors, activate the NF-\u03baB signaling pathway, leading to cardiomyocyte pyroptosis, a key mechanism in heart failure progression. It also reviewed therapeutic approaches to inhibit NF-\u03baB and reduce pyroptosis.", "population_specificity": "Not specified (focus on molecular mechanisms in cardiovascular diseases)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:20.055310+00:00"}
{"study_id": 101097, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in the development of age-related noncommunicable diseases (NCDs) and their interaction with lifestyle factors.", "results_summary": "The study found that AGEs, along with other modified biomolecules, contribute to the development of age-related NCDs by interacting with oxidative stress, insulin resistance, and systemic dysregulation. Lifestyle interventions, such as dietary changes, may help mitigate these effects.", "population_specificity": "General population, with comparative insights from hunter-gatherer societies.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:20.592327+00:00"}
{"study_id": 101099, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the effects of dietary reduction of Advanced Glycation End Products (AGEs) and MAF supplementation on cognitive function in elderly rehabilitation participants.", "results_summary": "MAF supplementation significantly improved cognitive function after 6 months, while dietary modulation showed cognitive benefits after 12 months. Plasma AGE levels increased only in the control group, with no change in the intervention groups.", "population_specificity": "Elderly participants (>60 years) attending a daycare rehabilitation facility without cognitive dysfunction, severe anemia, terminal cancer, or neurodegenerative diseases.", "effective_dosage": "Not specified", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:21.461375+00:00"}
{"study_id": 101100, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to understand how protein glycation impacts cardiomyocytes and explore therapeutic strategies to mitigate its effects.", "results_summary": "The study found that glycation affects cardiomyocytes through extracellular and intracellular mechanisms, impairing contractility and increasing cardiovascular disease risk. Therapeutic attempts to reduce glycation have shown mixed results in clinical trials.", "population_specificity": "Not specified (general focus on conditions like diabetes, rheumatoid arthritis, smoking, and aging).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:22.288915+00:00"}
{"study_id": 101098, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to review the role of HMGB1, particularly its interaction with RAGE (receptor for advanced glycation end products), in drug-induced organic damage and its potential as a therapeutic target.", "results_summary": "The study highlights HMGB1's regulatory role in inflammation and immune response via interaction with RAGE, suggesting its potential as a therapeutic target for mitigating drug-induced toxicity and inflammatory damage. Excessive HMGB1 release exacerbates inflammation and cellular damage in various diseases.", "population_specificity": "Not specified (review article, not a clinical study)", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:22.334944+00:00"}
{"study_id": 101101, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to review the roles of Advanced Glycation End Products (AGEs) and their receptor (sRAGE) in pulmonary diseases and explore their potential as biomarkers and therapeutic targets.", "results_summary": "The study found that AGEs and RAGE contribute to the pathogenesis of various lung diseases, while sRAGE exhibits anti-inflammatory, antioxidant, and anti-fibrotic properties, making it a promising therapeutic target.", "population_specificity": "Not specified (review of existing studies on pulmonary diseases).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:22.698087+00:00"}
{"study_id": 101102, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 70, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in disease initiation and progression, and discuss nanoparticle-based strategies for targeting the AGE-RAGE pathway.", "results_summary": "The abstract highlights that AGEs contribute to disease development by binding to RAGEs, and nanoparticles offer advantages like high bioavailability and biocompatibility for targeting this pathway.", "population_specificity": "Not specified", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:25.906959+00:00"}
{"study_id": 101103, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in the pathogenesis of diabetic kidney disease (DKD) and discuss potential interventions to mitigate AGEs accumulation.", "results_summary": "The study found that AGEs contribute to DKD through mechanisms like oxidative stress, inflammation, and cell death, and elevated AGE levels correlate with clinical and morphological DKD manifestations. Potential strategies to reduce AGEs accumulation and prevent adverse renal outcomes were also discussed.", "population_specificity": "Diabetic patients, particularly those with or at risk for diabetic kidney disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:27.933587+00:00"}
{"study_id": 101105, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of advanced glycation end products (AGEs) in diabetic distal symmetric polyneuropathy and their potential as a therapeutic target.", "results_summary": "The study found that AGEs contribute to neuroinflammation by activating inflammatory cytokines, which are linked to diabetic neuropathy and neuropathic pain. Anti-inflammatory interventions targeting AGEs may offer therapeutic benefits for diabetic neuropathy.", "population_specificity": "Patients with diabetic distal symmetric polyneuropathy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:28.281121+00:00"}
{"study_id": 101106, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the pathological association between diabetes and cancer progression, focusing on the role of Advanced Glycation End Products (AGEs) in tumorigenesis and potential therapeutic intersections.", "results_summary": "The study found that AGEs are linked to cancer etiology, with increased levels observed in various tumor types, including leiomyosarcomas, adenocarcinomas, and squamous cell carcinomas. Elevated RAGE expression in aggressive breast cancer suggests a potential role in enhancing tumor malignancy.", "population_specificity": "Not specified (review of existing literature)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:28.517932+00:00"}
{"study_id": 101107, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to explore the role of the AGEs-RAGE axis in chronic inflammation and disease progression, as well as potential strategies to inhibit this axis.", "results_summary": "The study found that AGEs-RAGE activation promotes chronic inflammation via pathways like NF-\u03baB, exacerbating diseases like diabetes, atherosclerosis, and tumors. It also highlighted potential therapeutic strategies, including AGEs inhibitors and RAGE antagonists.", "population_specificity": "Individuals with diabetes, atherosclerosis, and tumors (broadly discussed, not a specific clinical cohort).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:28.879070+00:00"}
{"study_id": 101111, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not specify a study goal related to Advanced Glycation End Products.", "results_summary": "The abstract does not report any findings related to Advanced Glycation End Products.", "population_specificity": "Not specified", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:29.240006+00:00"}
{"study_id": 101108, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 50, "study_goal": "The researchers aimed to elucidate the relationship between diabetes and osteoporosis, focusing on the role of Advanced Glycation End Products (AGEs) in impairing osteoblast differentiation and bone formation.", "results_summary": "The study found that AGE-RAGE signaling activation inhibits osteoblast differentiation and bone formation, while high glucose environments induce osteoblast ferroptosis, contributing to osteoporosis. Hyperglycemia also reduces sex hormone secretion, further impairing bone mineral density maintenance.", "population_specificity": "Diabetic patients (specific demographics not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:29.842026+00:00"}
{"study_id": 101110, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the interaction between aldosterone and glycation in diabetic nephropathy and cardiovascular diseases, focusing on the cross-talk between AGEs-RAGE and Aldo-MR pathways.", "results_summary": "The study highlights that AGEs-RAGE and Aldo-MR pathways contribute to inflammation, oxidative stress, and fibrosis, but the cross-talk between these pathways remains unresolved. Therapeutic drugs targeting these pathways have been discovered, but their mutual interactions are not fully understood.", "population_specificity": "Patients with diabetic nephropathy and cardiovascular diseases.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:30.688398+00:00"}
{"study_id": 101112, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products in the neurodegeneration pathways associated with Diabetic Retinopathy and identify potential therapeutic interventions.", "results_summary": "The study found that Advanced Glycation End Products contribute to neurodegeneration in Diabetic Retinopathy through oxidative stress and mitochondrial dysfunction, and targeting these pathways may offer therapeutic benefits.", "population_specificity": "Individuals with Diabetic Retinopathy or diabetes mellitus.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:34.705724+00:00"}
{"study_id": 101113, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to review the evidence linking Type 2 diabetes (T2D) to Parkinson's disease (PD) pathology and discuss potential alternative pharmacological interventions for PD.", "results_summary": "The abstract summarizes epidemiological, preclinical, and clinical evidence suggesting insulin resistance and chronic inflammation contribute to overlapping aetiologies of T2D and PD, but does not specifically address Advanced Glycation End Products.", "population_specificity": "Not specified (general discussion of T2D and PD populations).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:35.980572+00:00"}
{"study_id": 101116, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the impact of space travel on biomarkers, including Advanced Glycation End Products (AGEs), and their role in accelerated aging and metabolic dysregulation.", "results_summary": "The abstract suggests that space travel alters biomarkers like AGEs, contributing to accelerated aging and metabolic pathway disruptions, which may inform precision health strategies.", "population_specificity": "Astronauts and space-related research models.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:36.445541+00:00"}
{"study_id": 101119, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in the pathophysiology of diabetic neuropathy, including their impact on nerve function and metabolic dysregulation.", "results_summary": "The abstract highlights that AGEs contribute to nerve damage in diabetic neuropathy through metabolic dysregulation and inflammatory processes, but it does not provide specific efficacy or safety data on AGEs.", "population_specificity": "Individuals with diabetic neuropathy (no specific demographic details provided).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:37.053507+00:00"}
{"study_id": 101115, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in contributing to cardiovascular risk and disease progression in chronic kidney disease (CKD) patients.", "results_summary": "The study found that AGEs, along with other uraemic retention solutes, contribute to post-translational protein modifications, which may drive inflammation, oxidative stress, fibrosis, and vascular damage in CKD patients, potentially increasing cardiovascular risk and disease progression. These modifications could serve as diagnostic biomarkers or therapeutic targets.", "population_specificity": "Patients with chronic kidney disease (CKD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:37.086303+00:00"}
{"study_id": 101114, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to review the role of endophytic metabolites in combating Advanced Glycation End Products (AGEs) and their impact on non-communicable diseases (NCDs), as well as elucidate AGEs formation, absorption, metabolism, and harmful effects.", "results_summary": "The review highlights that endophytic metabolites modulate signaling pathways and enhance gut microbiota digestibility by targeting the AGEs/RAGE axis, exhibiting anti-AGEs activities similar to host plant metabolites but more cost-effectively and sustainably.", "population_specificity": "Not specified (review of existing literature)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:37.167896+00:00"}
{"study_id": 101118, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to examine the role of VAP-1 in diabetes and its complications, including its link to advanced glycation end-products (AGEs), and explore its potential as a biomarker and therapeutic target.", "results_summary": "The study highlights VAP-1's involvement in diabetic complications through oxidative stress, inflammation, and AGE formation, suggesting its inhibition as a promising treatment. Soluble VAP-1 may serve as a biomarker for diabetes-related conditions.", "population_specificity": "Diabetic patients and related conditions (e.g., cardiovascular disease, retinopathy, nephropathy, neuropathy, cancer, metabolic dysfunction-associated fatty liver disease).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:37.713310+00:00"}
{"study_id": 101120, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in diabetic neuropathy and review emerging therapeutic strategies to address it.", "results_summary": "The study highlights that AGEs contribute to diabetic neuropathy through metabolic pathways, alongside oxidative stress and cytokine release, but does not provide specific efficacy data on AGEs as a therapeutic target.", "population_specificity": "Patients with diabetic neuropathy, including those with pain, distal symmetric polyneuropathy, and autonomic neuropathy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:38.551107+00:00"}
{"study_id": 101121, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore corneal epithelial changes in diabetic patients, focusing on mechanisms involving Advanced Glycation End Products (AGEs) and their impact on ocular health.", "results_summary": "The study found that AGEs contribute to corneal epithelial alterations in diabetes, linked to hyperglycemia, oxidative stress, and impaired wound healing, increasing risks of corneal erosions and dry eye syndrome.", "population_specificity": "Diabetic patients", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:41.366615+00:00"}
{"study_id": 101122, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the pathological role of glycative stress (including Advanced Glycation End Products) in retinal dysfunction and explore whether dietary strategies (low glycemic index diets) could mitigate retinal diseases like AMD.", "results_summary": "The study found that higher glycemic index diets promote glycative stress and AGE accumulation, which are cytotoxic and linked to retinal dysfunction. Lower glycemic index diets were protective against early AMD features in mice and AMD progression in humans.", "population_specificity": "Laboratory animals (mice) and human clinical epidemiologic data.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:43.498881+00:00"}
{"study_id": 101123, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the diagnostic, predictive, and therapeutic value of S100A9 in inflammatory-related cardiovascular diseases (CVD) and its molecular mechanisms involving advanced glycation end products (AGEs).", "results_summary": "The study found that S100A9, which interacts with the receptor for advanced glycation end products (RAGE), is a key biomarker for diagnosing and predicting CVD. It plays a role in regulating inflammatory response, fibrosis, vascular calcification, and endothelial barrier function in CVD.", "population_specificity": "Not specified (general cardiovascular disease context).", "effective_dosage": "Not mentioned.", "study_duration": "Not mentioned.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:44.347008+00:00"}
{"study_id": 101124, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to summarize the role of autophagy in diabetic nephropathy (DN) and explore how miRNA and lncRNA regulate autophagy during DN progression.", "results_summary": "The abstract highlights that autophagy dysregulation contributes to DN progression, and miRNA and lncRNA play a role in regulating autophagy, impacting renal cell injury, mitochondrial dysfunction, inflammation, and fibrosis. Targeting these ncRNAs may offer potential interventions for DN.", "population_specificity": "Diabetic patients with nephropathy", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:44.477444+00:00"}
{"study_id": 101127, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether dried okra extract (DOE) supplementation affects renal function, lipid profile, and inflammatory gene expression related to Advanced Glycation End Products (AGEs) in diabetic nephropathy patients.", "results_summary": "The study found no significant differences in lipid profile, kidney function indices, sRAGE levels, or RAGE-related inflammatory gene expression after 10 weeks of DOE supplementation compared to placebo.", "population_specificity": "64 patients with diabetic nephropathy (a complication of type 2 diabetes).", "effective_dosage": "125 mg daily.", "study_duration": "10 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:45.446865+00:00"}
{"study_id": 101125, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to review the effects of hyperglycemia and Advanced Glycation End Products (AGEs) on intervertebral disc degeneration (IDD).", "results_summary": "The study found that AGEs accumulation, often linked to high glucose and high-fat diets, contributes to adverse effects on the intervertebral disc, including cell senescence, apoptosis, pyroptosis, and ECM degradation. It highlights the need for further research into mechanisms and targeted treatments for high glucose-induced IDD.", "population_specificity": "Patients with intervertebral disc degeneration, particularly those with metabolic disorders like diabetes.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:45.636463+00:00"}
{"study_id": 101128, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to propose a new classification of Advanced Glycation End Products (AGEs) and describe their role in the pathogenesis of metabolic and age-related diseases.", "results_summary": "The study found that AGEs contribute to irreversible tissue changes, leading to micro- and macroangiopathies, organ failure, and increased risks of Alzheimer's disease and cancers. It also proposed a new classification of AGEs and highlighted their diagnostic and therapeutic potential in conditions like diabetes, atherosclerosis, and SARS-CoV-2 infection.", "population_specificity": "General discussion of metabolic disorders (e.g., diabetes, atherosclerosis, obesity) and aging populations.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:45.848961+00:00"}
{"study_id": 101129, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to determine if skin autofluorescence (SAF) advanced glycation end products (AGEs) could serve as a reliable biomarker for uveitis/scleritis activity in patients with systemic inflammatory diseases.", "results_summary": "The study found no significant difference in SAF AGE levels between active uveitis/scleritis patients and healthy controls. Multivariate analysis showed decreased SAF AGE levels were associated with active ocular inflammation, but the authors concluded SAF AGE was not a reliable biomarker for indicating disease activity.", "population_specificity": "Systemic immune-related disease patients with active non-infectious uveitis/scleritis and age-matched healthy controls.", "effective_dosage": "Not specified", "study_duration": "Cross-sectional study (data collected from October 2019 to March 2020)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:48.560341+00:00"}
{"study_id": 101130, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to clarify the potential role of metformin in alleviating depression in diabetic patients by examining its anti-inflammatory effects and impact on advanced glycation end products.", "results_summary": "The study found that metformin reduces inflammation by inhibiting pro-inflammatory molecules like NF-kB and angiotensin II, normalizing gut microbiota, and decreasing advanced glycation end products, which collectively may alleviate depression in diabetic patients. Clinical and experimental studies support metformin's antidepressant effects via peripheral and central nervous system mechanisms.", "population_specificity": "Patients with type 2 diabetes and comorbid depression.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:49.499915+00:00"}
{"study_id": 101131, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to examine the mechanistic pathways by which phytocompounds from conventional plants could control and treat diabetic nephropathy, focusing on the role of Advanced Glycation End Products (AGEs).", "results_summary": "The study found that AGEs accumulate in the kidney during diabetes, altering renal architecture and impairing function, and highlighted potential therapeutic benefits of bioactive substances in managing oxidative stress, inflammation, and autophagy.", "population_specificity": "Individuals with diabetes, particularly those at risk of or suffering from diabetic nephropathy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:51.318732+00:00"}
{"study_id": 101132, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in diabetic retinopathy (DR) by examining glucose transport, metabolism, and their impact on retinal neurovascular dysfunction.", "results_summary": "The study found that AGEs, along with other biochemical pathways, contribute to oxidative stress, microangiopathy, neurodegeneration, and inflammation in DR by enhancing glucose uptake and metabolism under diabetic conditions.", "population_specificity": "Individuals with diabetic retinopathy (DR).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:52.181955+00:00"}
{"study_id": 101133, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to review material-based strategies for addressing diabetic bone repair deficiencies, including the role of Advanced Glycation End Products (AGEs) in bone microenvironment deterioration.", "results_summary": "The study highlights that excessive AGEs contribute to bone fragility and poor healing in diabetes, alongside other factors like ROS and immune imbalance. Material-based strategies targeting AGEs, ROS, and infection resistance show promise for diabetic bone regeneration.", "population_specificity": "Elderly diabetic patients with bone fragility and poor healing.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:52.591509+00:00"}
{"study_id": 101135, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to examine the role of Advanced Glycation End Products (AGEs) within the context of Cardiovascular-Kidney-Metabolic (CKM) syndrome, focusing on their pathophysiological mechanisms and connections to related diseases.", "results_summary": "The abstract highlights that AGEs are part of the interconnected molecular mechanisms underlying CKM syndrome, contributing to conditions like hyperglycemia, oxidative stress, and chronic inflammation, but does not provide specific findings on AGEs' direct effects.", "population_specificity": "Not specified (general discussion of CKM syndrome in industrialized nations).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:53.209410+00:00"}
{"study_id": 101136, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the relationship between soluble receptor for advanced glycation end products (sRAGE) and obesity in adults, focusing on BMI and waist circumference.", "results_summary": "Higher circulating sRAGE concentrations were associated with lower BMI and waist circumference among healthy adults, suggesting a potential protective effect against obesity. The meta-analysis included 13 studies, with a median sRAGE concentration of 934.92 pg/ml linked to reduced obesity indices.", "population_specificity": "Apparently healthy adults, adults with obesity, or obesity-related disorders, aged over 18 years.", "effective_dosage": "Median circulating sRAGE concentration of 934.92 pg/ml (specific dosage not provided).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:54.437554+00:00"}
{"study_id": 101137, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether modulating AGE metabolism through specific diets (Mediterranean vs. low-fat) could delay kidney function decline in T2DM patients with coronary heart disease.", "results_summary": "The Mediterranean diet resulted in a slower decline of eGFR compared to the low-fat diet in patients with mildly decreased eGFR, reduced MG levels, and increased GloxI expression. Higher MG levels post-intervention were associated with a greater probability of eGFR decline.", "population_specificity": "T2DM patients with coronary heart disease and eGFR \u2265 30 ml/min/1.73 m\u00b2 (n=540 from the CORDIOPREV study).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:54.871501+00:00"}
{"study_id": 101138, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to review the role of methylglyoxal (MGO) in generating advanced glycation end products (AGEs) and its implications in metabolic and cardiovascular diseases, as well as potential therapeutic strategies.", "results_summary": "The study highlights MGO's involvement in metabolic disturbances and its association with disorders like diabetes and cardiovascular diseases. It discusses potential inhibitors and scavengers targeting MGO and AGEs for treatment.", "population_specificity": "Not specified (general review of pathological mechanisms and potential treatments).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:57.219341+00:00"}
{"study_id": 101140, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the associations between skin advanced glycation end products (AGEs) and subclinical atherosclerosis, arterial stiffness, and hypertension, particularly in relation to coronary heart disease (CHD).", "results_summary": "Higher skin AGEs were associated with carotid plaques, increased carotid intima-media thickness, coronary artery calcification, and arterial stiffness, but not with hypertension. These associations were stronger in men and individuals with diabetes or chronic kidney disease.", "population_specificity": "3001 participants (mean age 73, 57% women) from the population-based Rotterdam Study.", "effective_dosage": "Not specified", "study_duration": "Cross-sectional study (no intervention duration)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:58.244174+00:00"}
{"study_id": 101141, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to explore the pathogenic and therapeutic connections between Alzheimer's Disease (AD) and the blood-brain barrier (BBB), focusing on the role of receptors like RAGE (receptor for advanced glycation end products) in AD pathogenesis.", "results_summary": "The abstract highlights that RAGE is implicated in AD's pathogenesis, particularly in BBB dysfunction, but does not provide specific findings on its effects. The review discusses potential therapeutic strategies targeting the BBB, including RAGE, but lacks detailed results on efficacy or safety.", "population_specificity": "Not specified (general focus on Alzheimer's Disease and BBB dysfunction)", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:38:59.838604+00:00"}
{"study_id": 101146, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to investigate the role of Advanced Glycation End Products (AGEs) in uterine collagen cross-linking and their implications for uterine disorders.", "results_summary": "AGEs were found to disrupt embryo development, decidualization, implantation, and trophoblast invasion, while altered collagen cross-link density was associated with preterm birth and uterine fibroids.", "population_specificity": "Uterine tissue and related disorders (e.g., fibroids, preterm birth).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:00.547069+00:00"}
{"study_id": 101142, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the potential role of soluble RAGE (sRAGE) in mitigating the effects of Advanced Glycation End Products (AGEs) on cardiovascular disorders (CVD) and its potential as a therapeutic target.", "results_summary": "The study found that AGEs contribute to cardiovascular disorders through mechanisms like protein alteration, tissue stiffening, free radical generation, and inflammation. While sRAGE may have anti-inflammatory and anti-oxidant properties, the relationship between sRAGE and CVD remains inconsistent, requiring further research.", "population_specificity": "Not specified (general discussion of AGEs and CVD).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:00.549225+00:00"}
{"study_id": 101145, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify biological subphenotypes in ARDS patients treated with HFNO, using biomarkers including receptor for advanced glycation end products (RAGE).", "results_summary": "The study identified two subphenotypes (hyperinflammatory and hypoinflammatory) in HFNO-treated ARDS patients, with the hyperinflammatory group showing higher biomarker levels (including RAGE) and worse outcomes. The HAIS score, based on IL-8 and sST2, effectively distinguished these subphenotypes.", "population_specificity": "ARDS patients supported with high-flow nasal oxygen (HFNO).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:01.006049+00:00"}
{"study_id": 101148, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of metabolic dysfunction, including glucose metabolism impairment, in the development and progression of Alzheimer's disease.", "results_summary": "The abstract highlights that Alzheimer's disease may be linked to metabolic alterations, particularly impaired glucose metabolism, mitochondrial dysfunction, and oxidative stress, but does not provide specific findings on Advanced Glycation End Products.", "population_specificity": "Not specified (general discussion of Alzheimer's disease mechanisms).", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:02.327628+00:00"}
{"study_id": 101147, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare AGE and RAGE levels in diabetic and non-diabetic periodontitis patients and assess their relationship with periodontal disease severity.", "results_summary": "Elevated AGE levels were found in diabetic periodontitis patients compared to non-diabetic patients, and AGE/RAGE levels were associated with clinical attachment loss and periodontal pocket depth. Potential confounding factors like genetic and methodological differences also influenced AGE/RAGE variation.", "population_specificity": "2794 patients aged 15-75 years with diabetic or non-diabetic periodontitis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:02.905287+00:00"}
{"study_id": 101149, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to summarize the current evidence on the effects of phytochemicals, including their modulation of Advanced Glycation End Products pathways, on diabetic neuropathy.", "results_summary": "The study found that phytochemicals like flavonoids, terpenes, alkaloids, stilbenes, and tannins can modulate pathways involved in diabetic neuropathy, including reducing oxidative stress and inflammation, and promoting nerve repair. These compounds may offer a complementary approach to conventional treatments by targeting multiple pathological mechanisms.", "population_specificity": "Patients with diabetic neuropathy (a complication of diabetes mellitus affecting peripheral nerves).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:04.888640+00:00"}
{"study_id": 101150, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not mention Advanced Glycation End Products or its study goals.", "results_summary": "The abstract does not discuss Advanced Glycation End Products or its effects.", "population_specificity": "Patients with hereditary transthyretin (ATTRv) amyloidosis with polyneuropathy (FAP).", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:05.397178+00:00"}
{"study_id": 101151, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of phenolic compounds in mitigating diabetes-related oxidative stress, AGEs production, and inflammation.", "results_summary": "The abstract suggests that phenolic compounds may offer therapeutic potential in addressing diabetes complications by targeting oxidative stress, AGEs accumulation, and inflammation, though specific results are not detailed.", "population_specificity": "Not specified (general diabetes-related context).", "effective_dosage": "Not available.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:06.736820+00:00"}
{"study_id": 101154, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the role of Advanced Glycation End Products (AGEs) in upregulating LOX-1 and their impact on atherosclerosis and cardiovascular disease severity.", "results_summary": "The study found that AGEs, along with other factors like cytokines and shear stress, can upregulate LOX-1, contributing to proatherogenic events. It also highlighted the role of OLR1 gene variants in modulating cardiovascular disease severity, with some isoforms like LOXIN offering protective effects.", "population_specificity": "Not specified (general discussion of cardiovascular disease mechanisms)", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:08.638220+00:00"}
{"study_id": 101152, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of yacon flour consumption and an energy-restricted diet on intestinal microbiota, including correlations with advanced glycation end products (AGEs).", "results_summary": "The study found a negative correlation between AGEs and the genera Ruminococcus and Prevotella, suggesting yacon flour may influence AGE-related microbiota changes. Yacon consumption also increased beneficial bacteria like Bifidobacterium and Blautia.", "population_specificity": "Adults with excess body weight (n=21).", "effective_dosage": "25 g of yacon flour daily at breakfast.", "study_duration": "6 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:08.999905+00:00"}
{"study_id": 101155, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to understand the role of Advanced Glycation End Products (AGEs) in diabetes-induced cardiovascular complications, particularly cardiomyopathy.", "results_summary": "The study found that AGEs contribute to mitochondrial uncoupling, glucotoxicity, lipotoxicity, and cardiac dysfunction in diabetic hearts, leading to overt heart failure. It also identified oxidative stress, inflammatory cytokines, and other factors like hypertension as major contributors to cardiomyopathy.", "population_specificity": "Diabetic patients with cardiovascular complications, particularly those with cardiomyopathy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:09.593284+00:00"}
{"study_id": 101156, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the efficacy of individualized PEEP in improving oxygenation and reducing atelectasis in patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP).", "results_summary": "The study found that individualized PEEP improved PaO\u2082 compared to traditional lung-protective ventilation strategies, suggesting better oxygenation outcomes. However, the abstract does not provide detailed statistical results or clinical relevance for Advanced Glycation End Products.", "population_specificity": "Patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP).", "effective_dosage": "Not Assessed", "study_duration": "Not Assessed", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:10.408601+00:00"}
{"study_id": 101157, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine the role of calprotectin in vascular calcification and whether inhibiting it (via paquinimod or targeting receptors like Advanced Glycation End Products) could prevent calcification in CKD patients.", "results_summary": "Calprotectin was identified as a key contributor to vascular calcification, with elevated levels linked to poor CV outcomes and mortality in CKD patients. Pharmacological inhibition of calprotectin (via paquinimod or targeting its receptors) reduced calcification in human VSMCs, mouse models, and uremic patient sera.", "population_specificity": "Patients with chronic kidney disease (CKD) from Spain, France, and Sweden, as well as primary human VSMCs and mouse models.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:11.761587+00:00"}
{"study_id": 104036, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 30, "study_goal": "The researchers were attempting to determine the cause of jaundice and liver dysfunction in a young woman with a recent history of antibiotic use.", "results_summary": "The study identified hepatomegaly and jaundice in a previously healthy patient following amoxicillin-clavulanic acid use, but did not assess Alanine's effects.", "population_specificity": "A 21-year-old woman with painless jaundice and fatigue.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:20.379477+00:00"}
{"study_id": 104033, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether serum bilirubin levels, including associations with alanine transaminase, are linked to lung cancer risk and subtypes.", "results_summary": "The study found that low serum bilirubin levels, along with elevated aspartate transaminase and alanine transaminase, were risk factors for lung cancer, particularly lung adenocarcinoma (LAC). Serum bilirubin levels varied significantly among different lung cancer subtypes.", "population_specificity": "363 lung cancer patients and 363 age-and gender-matched healthy subjects.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:21.080167+00:00"}
{"study_id": 104032, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to compare the efficacy of percutaneous catheter drainage (PCD) combined with peritoneal dialysis (PD) versus conventional treatment in reducing inflammatory markers and improving clinical outcomes in severe acute pancreatitis (SAP) patients.", "results_summary": "The combination of PCD and PD significantly reduced inflammatory cytokine levels, improved organ function markers (including alanine aminotransferase), and shortened hospital stays and symptom amelioration time compared to conventional treatment.", "population_specificity": "64 patients with severe acute pancreatitis.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:21.228353+00:00"}
{"study_id": 104031, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to examine the differential improvements in cardiovascular risk factors, including alanine transaminase (ALT), in Japanese T2DM patients treated with ipragliflozin.", "results_summary": "The study found significant improvements in ALT and other liver enzymes in the ipragliflozin group, particularly in high-risk subgroups, correlating with changes in body weight, HbA1c, and insulin resistance. No significant improvements were observed in lipid parameters or blood pressure.", "population_specificity": "Japanese patients with type 2 diabetes mellitus (T2DM).", "effective_dosage": "50 mg/day of ipragliflozin.", "study_duration": "12-24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:21.427580+00:00"}
{"study_id": 104030, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to examine the effect of virgin olive oil on alanine aminotransferase (ALT) levels and the severity of steatosis in NAFLD patients undergoing a weight-loss diet.", "results_summary": "The study found a significant decrease in ALT levels in the control group, suggesting that a low-calorie diet enriched with olive oil, combined with weight reduction, improves hepatic enzyme levels.", "population_specificity": "50 patients with nonalcoholic fatty liver disease (mean age 45.91 \u00b1 9.61 years, mean BMI 29.7 \u00b1 0.58 kg/m\u00b2).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:21.554384+00:00"}
{"study_id": 104035, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers investigated whether curcumin could reduce iron overload and improve liver function, as indicated by ALT and AST levels, in \u03b2-thalassemia major patients.", "results_summary": "Curcumin significantly reduced serum levels of ALT and AST, indicating improved liver function, and decreased nontransferrin bound iron (NTBI), suggesting reduced iron burden. No significant changes were observed in hepcidin or other variables.", "population_specificity": "\u03b2-thalassemia major patients (n=68)", "effective_dosage": "1,000 mg curcumin (500 mg capsules twice daily)", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:21.704000+00:00"}
{"study_id": 104034, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine the magnitude and kinetics of change in liver stiffness in hepatitis B patients treated with nucleot(s)ide analogs, particularly focusing on the role of baseline alanine aminotransferase levels.", "results_summary": "The study found that antiviral therapy led to a progressive decline in liver stiffness over time, with greater declines observed in patients with high baseline alanine aminotransferase levels, viral load, and liver stiffness. The reductions were statistically significant at all measured time points (6 months to 5 years).", "population_specificity": "Adults with hepatitis B who underwent transient elastography before and after starting nucleot(s)ide analogs therapy.", "effective_dosage": "Not specified", "study_duration": "Follow-up periods ranged from 6 months to 5 years.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:21.878862+00:00"}
{"study_id": 104029, "supplement_id": 863, "safety_score": "75", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to assess the safety and efficacy of vesatolimod, a toll-like receptor 7 agonist, in viremic chronic hepatitis B (CHB) patients not on oral antiviral treatment, with a focus on alanine aminotransferase levels.", "results_summary": "Vesatolimod was safe and well-tolerated, with most adverse events being mild or moderate. However, no clinically meaningful HBsAg decline was observed, and efficacy outcomes (e.g., HBsAg loss) were minimal.", "population_specificity": "Viremic chronic hepatitis B patients (64.1% male, 60.9% HBeAg-negative) not currently on oral antiviral treatment.", "effective_dosage": "1-, 2-, or 4-mg once weekly for 12 weeks (vesatolimod); 300-mg tenofovir disoproxil fumarate daily for 48 weeks.", "study_duration": "12 weeks (vesatolimod), 48 weeks (tenofovir).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:23.578880+00:00"}
{"study_id": 104041, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 30, "study_goal": "The study does not focus on Alanine but rather describes a case of severe alcoholic hepatitis and its clinical course.", "results_summary": "The abstract reports on a patient with severe alcoholic hepatitis, treated with prednisolone, but does not discuss Alanine's effects.", "population_specificity": "A 33-year-old Caucasian male with a history of heavy alcohol use.", "effective_dosage": "Not mentioned", "study_duration": "Prednisolone was administered for 28 days.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:28.133624+00:00"}
{"study_id": 104038, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to model the pharmacokinetics and pharmacodynamics of rivaroxaban in NVAF patients, including the influence of alanine aminotransferase on its pharmacokinetics.", "results_summary": "The study found that rivaroxaban's pharmacokinetics were influenced by creatinine clearance, alanine aminotransferase, and use of CYP3A4 or P-gp inhibitors, with PT measurements showing medium predictive ability.", "population_specificity": "Non-valvular atrial fibrillation (NVAF) patients under rivaroxaban therapy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "CYP3A4 or P-gp inhibitors", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:28.753745+00:00"}
{"study_id": 104039, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the efficacy and safety of pyronaridine-artesunate versus artemether-lumefantrine for treating uncomplicated Plasmodium falciparum malaria in children, not specifically to evaluate Alanine.", "results_summary": "The study did not focus on Alanine's effects but noted no participants had elevated alanine aminotransferase levels (>3 times the upper limit of normal).", "population_specificity": "Children aged 6 months to \u226412 years with uncomplicated P. falciparum malaria in Western Kenya.", "effective_dosage": "Not specified for Alanine.", "study_duration": "3 days (for malaria treatment).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:29.116996+00:00"}
{"study_id": 104040, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treating chronic hepatitis B virus (HBV) infection, focusing on renal and bone safety.", "results_summary": "At 96 weeks, TAF was non-inferior to TDF in viral suppression rates, with significantly improved renal and bone safety profiles, including smaller decreases in bone mineral density and better renal function preservation.", "population_specificity": "Patients with chronic HBV infection (HBeAg-positive and HBeAg-negative).", "effective_dosage": "25 mg TAF or 300 mg TDF once daily.", "study_duration": "96 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:29.229974+00:00"}
{"study_id": 104037, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers compared the safety profiles of pazopanib and sunitinib in Asian and non-Asian subpopulations, focusing on adverse events, including alanine aminotransferase (ALT) increases.", "results_summary": "Among Asian patients, increased alanine aminotransferase (grade 3, 12%; grade 4, 1%) was a common adverse event with pazopanib, but the study did not assess alanine's standalone safety or efficacy.", "population_specificity": "Asian and non-Asian patients with advanced renal cell carcinoma.", "effective_dosage": "Pazopanib 800 mg once daily (continuous dosing); sunitinib 50 mg once daily in 6-week cycles (4 weeks on, 2 weeks off).", "study_duration": "Duration of exposure was similar between Asian and non-Asian patients, though exact length is unspecified.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:29.952697+00:00"}
{"study_id": 104043, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to assess the hepatoprotective efficacy of UDCA and vitamin E, including their impact on alanine aminotransferase levels, in pediatric B-cell ALL patients receiving methotrexate.", "results_summary": "UDCA showed a non-significant decline in alanine aminotransferase levels, while vitamin E had no notable effect. No significant liver fibrosis was observed in any group.", "population_specificity": "Pediatric patients with B-cell acute lymphoblastic leukemia (ALL) undergoing methotrexate maintenance therapy.", "effective_dosage": "Not specified for alanine (study focused on UDCA at 15 mg/kg/day and vitamin E at 400 mg/day).", "study_duration": "Duration not explicitly stated in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:30.556095+00:00"}
{"study_id": 104042, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were attempting to determine the effects of treating obstructive sleep apnea/nocturnal hypoxia on pediatric nonalcoholic fatty liver disease (NAFLD) severity and oxidative stress, not specifically Alanine.", "results_summary": "The study found that treatment with continuous positive airway pressure (CPAP) for sleep disordered breathing in children with NAFLD and obstructive sleep apnea/hypoxia may reverse parameters of liver injury and reduce oxidative stress. The data suggest CPAP as a potential therapy to prevent NAFLD progression in obese children with obstructive sleep apnea/hypoxia.", "population_specificity": "Adolescents (age 11.5 \u00b1 1.2 years; BMI 29.5 \u00b1 3.8 kg/m\u00b2) with biopsy-proven NAFLD and obstructive sleep apnea/hypoxia.", "effective_dosage": "Not mentioned", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:31.149301+00:00"}
{"study_id": 104044, "supplement_id": 863, "safety_score": "90", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of \u03b4-tocotrienol in improving liver function and reducing inflammatory and oxidative stress markers in patients with NAFLD.", "results_summary": "\u03b4-Tocotrienol significantly reduced serum aminotransferases, hs-CRP, MDA, and FLI scores compared to placebo but did not improve hepatic steatosis on ultrasound. No adverse effects were reported.", "population_specificity": "Patients aged >20 years with ultrasound-proven fatty liver disease, FLI \u226560, and persistent elevation of alanine transaminase.", "effective_dosage": "300 mg twice daily", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:31.733721+00:00"}
{"study_id": 104048, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were investigating the performance and role of percutaneous cholecystostomy (PC) in managing acute cholangitis, not specifically Alanine.", "results_summary": "The study found that PC was technically successful with no procedure-related mortality and led to significant biochemical improvement, including in alanine transaminase levels (P < .001).", "population_specificity": "High-risk elderly patients (median age 84 years) with acute cholangitis.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:36.658689+00:00"}
{"study_id": 104047, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were examining the safety, efficacy, and radiographic outcomes of sarilumab in adults with rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX).", "results_summary": "The study found that sarilumab had consistent safety profiles over 2 years, with common adverse events including increased alanine aminotransferase. Clinical response was similar regardless of initial treatment, and radiographic progression stabilized, with the best outcomes in patients initially receiving sarilumab 200 mg every 2 weeks.", "population_specificity": "Adults with rheumatoid arthritis and inadequate response to methotrexate (MTX-IR).", "effective_dosage": "150 mg or 200 mg every 2 weeks (q2w).", "study_duration": "Up to 2 years (1 year in the initial trial, followed by 1 year in the extension study).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:38.204744+00:00"}
{"study_id": 104045, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers sought to determine whether the difference in PAR4 signaling by the PAR4-120 variant (encoding alanine or threonine) is due to biased G protein signaling.", "results_summary": "The study found that the PAR4-120 variant (alanine vs. threonine) enhances both G protein signaling pathways, contributing to heightened platelet activation in certain populations.", "population_specificity": "Blacks and whites (comparative analysis of platelet activation by race).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:38.480441+00:00"}
{"study_id": 104049, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not address Alanine; it focuses on ketamine's efficacy in treating severe ethanol withdrawal.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Patients admitted to the ICU with delirium tremens.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:39.051949+00:00"}
{"study_id": 104050, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of interferon (IFN) on laboratory parameters, including alanine transaminase (ALT) levels, in patients with HCV-associated mixed cryoglobulinaemia.", "results_summary": "IFN made little or no difference in ALT levels at six months but may have decreased ALT levels at 18 months, though the evidence was of low certainty. The study did not focus on alanine as a supplement but rather on ALT as a biomarker.", "population_specificity": "Patients with HCV-associated mixed cryoglobulinaemia and active manifestations of vasculitis (cutaneous or glomerulonephritis).", "effective_dosage": "Not specified for alanine; IFN dosage varied by study.", "study_duration": "Studies ranged from six to 36 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:39.178865+00:00"}
{"study_id": 104052, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to assess the efficacy and safety of tacrolimus in treating refractory IgA nephropathy, not Alanine.", "results_summary": "The study found tacrolimus effective in reducing proteinuria in refractory IgA nephropathy patients, with 58.8% achieving complete remission and 14.7% partial remission. No results specific to Alanine were reported.", "population_specificity": "34 primary IgA nephropathy patients with refractory proteinuria.", "effective_dosage": "Not mentioned (tacrolimus dosage, not Alanine).", "study_duration": "At least 12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:39.354475+00:00"}
{"study_id": 104046, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the clinical efficiency of stem cell therapy in treating acute-on-chronic liver failure (ACLF), with a focus on outcomes including alanine transaminase (ALT) levels.", "results_summary": "The study found that ALT levels decreased significantly in the short-term after stem cell therapy compared to the control group (p\u2009<\u20090.00001). However, the abstract does not provide specific details on Alanine's standalone effects.", "population_specificity": "Patients with acute-on-chronic liver failure (ACLF).", "effective_dosage": "Not specified", "study_duration": "Follow-up periods included 1, 3, and 12 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:40.374129+00:00"}
{"study_id": 104051, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to quantify the association of circulating alanine levels with macrovascular disease, microvascular disease, and all-cause mortality in individuals with type 2 diabetes.", "results_summary": "Higher alanine levels were associated with a decreased risk of microvascular disease (HR 0.86; 95% CI 0.76, 0.98) after adjusting for extended classical risk factors. No significant association was found between alanine and macrovascular disease or mortality.", "population_specificity": "Individuals with type 2 diabetes (N=3587, including 655 macrovascular events, 342 microvascular events, and 632 mortality events).", "effective_dosage": "Not specified", "study_duration": "Follow-up duration not explicitly stated in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:41.701674+00:00"}
{"study_id": 104053, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify predictive factors for severe dengue in adults, including the role of elevated alanine aminotransferase (ALT) levels.", "results_summary": "The study found that elevated ALT levels (>120 U/L) were a significant predictor of severe dengue in adults, with an odds ratio of 3.51. Higher ALT levels were associated with severe dengue cases compared to non-severe cases.", "population_specificity": "Adults with dengue confirmed by a positive NS1 antigen test (median age 27.9 years, 45.4% male).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:44.627962+00:00"}
{"study_id": 104058, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the stability and performance of biochemical analytes, including alanine aminotransferase, in Barricor\u2122 plasma tubes versus regular lithium heparin tubes.", "results_summary": "The study found that Barricor\u2122 tubes improved stability for eight analytes, including alanine aminotransferase, allowing supplemental analysis within 72 hours of collection. Results showed good correlation and acceptable concordance between the two tube types.", "population_specificity": "Six healthy volunteers and nine intensive care unit patients.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:47.246426+00:00"}
{"study_id": 104056, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the impact of exercise and dietary interventions on alanine aminotransferase (ALT) levels and other metabolic markers in patients with NAFLD.", "results_summary": "The study found that aerobic exercise plus diet significantly improved ALT levels, while progressive resistance training reduced HOMA-IR. Dietary interventions were more effective for aminotransferase improvements, whereas exercise showed better results for insulin sensitivity and BMI reduction.", "population_specificity": "Patients diagnosed with nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:47.728828+00:00"}
{"study_id": 104055, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effectiveness of peginterferon alfa-2a (PegIFN) treatment in children with chronic hepatitis B (CHB).", "results_summary": "The study found that PegIFN alfa-2a was administered to children with CHB, but the abstract does not provide specific efficacy outcomes or adverse event data. The study design included randomized and non-randomized groups based on fibrosis status.", "population_specificity": "Children aged 3 to <18 years with chronic hepatitis B, including HBeAg-positive immune-active patients without advanced fibrosis/cirrhosis and those with advanced fibrosis.", "effective_dosage": "PegIFN alfa-2a was administered based on body surface area (BSA) category, with a reference dose of 180 \u03bcg/1.73 m\u00b2.", "study_duration": "48 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:48.086514+00:00"}
{"study_id": 104054, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy of NS-0200 (a combination including leucine) in reducing hepatic fat and improving lipid metabolism in subjects with NAFLD.", "results_summary": "High-dose NS-0200 reduced hepatic fat by 15.7% in subjects with elevated ALT, while low-dose and placebo showed no significant effect. Lipidomic analysis indicated dose-responsive improvements in lipid metabolism and fatty acid oxidation.", "population_specificity": "91 subjects with NAFLD (liver fat \u226515% by MRI-PDFF), with a subgroup analysis of those with ALT >50 U/L (n=35).", "effective_dosage": "Low-dose (1.1 g leucine/0.5 g metformin/0.5 mg sildenafil) or high-dose (1.1 g leucine/0.5 g metformin/1.0 mg sildenafil) twice daily.", "study_duration": "16 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:48.328614+00:00"}
{"study_id": 104057, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare the clinical presentations and evolution of acute hepatitis A (AHA) between HIV-infected and HIV-uninfected patients, including the role of alanine aminotransferase (ALT) levels.", "results_summary": "HIV-infected patients had lower peak ALT levels and less severe liver complications but delayed resolution of hepatitis compared to HIV-uninfected patients. Better viral suppression with cART improved ALT levels and reduced delayed resolution in HIV-infected patients.", "population_specificity": "Adult patients with acute hepatitis A (AHA), including HIV-infected and HIV-uninfected individuals, predominantly men who have sex with men.", "effective_dosage": "Not specified", "study_duration": "Data collected from May 2015 to May 2017 (retrospective analysis)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:48.389133+00:00"}
{"study_id": 104059, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to understand the mechanisms of kinase inhibitor (KI) hepatotoxicity and assess whether primary hepatocytes could predict such toxicity.", "results_summary": "The study found that 26 out of 34 KIs showed species-biased cytotoxicity, with 16 being more toxic to human hepatocytes. Human hepatocytes were more accurate (65%) than rat hepatocytes (59%) in predicting clinical hepatotoxicity.", "population_specificity": "Primary rat and human hepatocytes", "effective_dosage": "Concentrations normalized to maximal therapeutic blood levels (Cmax), ranging from 1- to 100-fold Cmax", "study_duration": "Measurements taken at 5 and 24 hours post-treatment", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:49.999451+00:00"}
{"study_id": 104060, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of Alanine scanning in identifying critical residues (Y652 and F656) in the hERG S6 domain for vandetanib binding, contributing to cardiotoxicity.", "results_summary": "Alanine scanning and in silico docking studies revealed that Y652 and F656 in the hERG S6 domain are critical for vandetanib binding, influencing its cardiotoxic effects. The study did not assess Alanine's direct effects or safety.", "population_specificity": "Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), rabbit Purkinje fibers, and HEK293 cells.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:51.439366+00:00"}
{"study_id": 104061, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine whether lubiprostone (LUB) improves gut permeability and reduces alanine aminotransferase levels in NAFLD patients with constipation.", "results_summary": "The abstract does not report specific results regarding alanine aminotransferase changes or gut permeability improvements, as the study is described as a protocol without outcome data.", "population_specificity": "Adult patients (20-85 years) with NAFLD, constipation, alanine aminotransferase \u226540 IU/L, steatosis grade \u22651, and fibrosis stage <4.", "effective_dosage": "LUB 12 \u03bcg and LUB 24 \u03bcg (frequency not specified).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:53.040240+00:00"}
{"study_id": 104064, "supplement_id": 863, "safety_score": "70", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and tolerability of trabectedin in combination with PLD for patients with platinum-sensitive relapsed ovarian cancer, including monitoring adverse events like alanine aminotransferase increase.", "results_summary": "The study found that alanine aminotransferase increase was a grade 3/4 adverse event in 7.8% of patients, indicating some liver-related toxicity. However, the overall safety profile was manageable, with no deaths attributed to drug-related adverse events.", "population_specificity": "Adults with platinum-sensitive relapsed ovarian cancer, pretreated with \u22651 platinum-containing regimen.", "effective_dosage": "Trabectedin at 1.1 mg/m\u00b2 (frequency not specified).", "study_duration": "Median treatment duration was 4.2 months (range 0.7-18.8).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:57.335468+00:00"}
{"study_id": 104066, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to assess the safety and antitumour activity of larotrectinib, a TRK inhibitor, in paediatric patients with advanced or metastatic solid or CNS tumours, regardless of TRK fusion status.", "results_summary": "Larotrectinib was well tolerated in paediatric patients and showed encouraging antitumour activity in those with TRK fusion-positive tumours. The recommended phase 2 dose was defined as 100mg/m\u00b2.", "population_specificity": "Infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid or CNS tumours.", "effective_dosage": "Doses adjusted for age and bodyweight, including 100 mg twice daily, 150 mg twice daily, and 100 mg/m\u00b2.", "study_duration": "Continuous 28-day schedule (specific total duration not detailed).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:57.458888+00:00"}
{"study_id": 104062, "supplement_id": 863, "safety_score": "70", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AC0010 (a third-generation EGFR TKI) in patients with advanced or recurrent NSCLC and acquired resistance to first-generation EGFR TKIs.", "results_summary": "AC0010 showed a well-tolerated safety profile with common adverse events including diarrhea, skin rash, and increased alanine transaminase levels. It demonstrated promising antitumor activity, particularly at doses of 350 mg or higher, with an overall response rate of 50.0% and significant reduction in T790M allele frequency.", "population_specificity": "Patients with advanced or recurrent NSCLC and acquired resistance to first-generation EGFR TKIs, including those with EGFR T790M mutation.", "effective_dosage": "Escalating daily doses from 50-600 mg, with 300 mg twice daily recommended as the phase II dose.", "study_duration": "28-day cycles (specific total duration not detailed in the abstract).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:57.615610+00:00"}
{"study_id": 104063, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate factors affecting HBsAg titres in different phases of chronic HBV infection, including the role of alanine aminotransferase (ALT) or necroinflammatory activity in HBeAg-negative chronic hepatitis B patients.", "results_summary": "The study found that HBsAg titres varied significantly across different phases of HBV infection, with age and HBV DNA correlating with serum HBsAg levels. In HBeAg-negative chronic hepatitis B patients, ALT or necroinflammatory activity was correlated with HBsAg titres.", "population_specificity": "1795 patients with chronic HBV infection, classified into HBeAg-positive chronic HBV infection, HBeAg-positive chronic hepatitis B, and HBeAg-negative chronic hepatitis B.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:39:57.784956+00:00"}
{"study_id": 104067, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the safety and efficacy of pyronaridine-artesunate and dihydroartemisinin-piperaquine versus first-line ACTs (artemether-lumefantrine and artesunate-amodiaquine) for malaria treatment and retreatment, not specifically focusing on Alanine.", "results_summary": "The study found that pyronaridine-artesunate and dihydroartemisinin-piperaquine were non-inferior to first-line ACTs in efficacy and well-tolerated, with transient elevations in transaminases and mild QTcF prolongation noted. Alanine-specific effects were not reported.", "population_specificity": "Adults and children aged 6 months and older with microscopically confirmed Plasmodium spp malaria in Burkina Faso, Guinea, and Mali.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:00.298711+00:00"}
{"study_id": 104069, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to compare the short-term efficacy and safety of DEB-TACE versus cTACE in treating hepatocellular carcinoma (HCC), not Alanine.", "results_summary": "The study found DEB-TACE had higher tumor response rates, lower recurrence rates, and better liver function outcomes compared to cTACE, but did not assess Alanine.", "population_specificity": "Chinese patients with hepatocellular carcinoma (HCC).", "effective_dosage": "Not mentioned (study focused on DEB-TACE and cTACE procedures).", "study_duration": "Follow-up at 1 week, 1 month, 3 months, and 6 months post-treatment.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:03.793707+00:00"}
{"study_id": 104073, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to test whether pretreatment with LY2979165, an alanine prodrug of a selective mGluR2 agonist, could attenuate the ketamine-induced BOLD signal in healthy volunteers.", "results_summary": "The study found that the highest dose of LY2979165 reduced the ketamine-evoked BOLD signal, with a relationship observed between signal reduction and increasing plasma levels of the active compound 2812223.", "population_specificity": "Healthy volunteers (N=16 subjects for LY2979165)", "effective_dosage": "20 and 60 mg", "study_duration": "Single acute doses", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:05.413149+00:00"}
{"study_id": 104072, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to assess fibrosis regression in chronic HCV patients treated with direct-acting agents compared to interferon-based regimens, including the impact on alanine transaminase levels.", "results_summary": "The study found significant improvement in post-treatment alanine transaminase levels, along with fibrosis regression detected in 27.5% of patients. Fibrosis regression was associated with sustained virological response in cirrhotic patients.", "population_specificity": "204 chronic HCV patients divided into three treatment groups.", "effective_dosage": "Not specified for alanine transaminase (focus was on HCV treatment regimens).", "study_duration": "At least 3 months post-treatment follow-up.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:05.479873+00:00"}
{"study_id": 104071, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of early fasting with total parenteral nutrition (TPN) versus early enteral nutrition (EN) on surgical site infection and metabolic outcomes in patients after sacrectomy.", "results_summary": "The study found that TPN support led to better incision healing, shorter hospitalization, and fewer complications compared to EN, with significant differences in serum protein, albumin, alanine aminotransferase, and bilirubin levels. However, EN was associated with lower gastrointestinal complications and faster return of bowel function.", "population_specificity": "Patients who underwent sacrectomy above the S3 level.", "effective_dosage": "Not specified", "study_duration": "Assessed at 7 and 14 days post-surgery", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:05.482570+00:00"}
{"study_id": 104074, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the therapeutic efficacy of mesenchymal stem cells (MSCs) in improving liver function, including alanine aminotransferase levels, compared to conventional treatments for liver disease.", "results_summary": "MSC therapy significantly improved liver function, including alanine aminotransferase levels, up to 6 months post-administration, but showed no benefit for other markers like prothrombin activity or cholinesterase. Optimal results were seen with a single injection via the hepatic artery using bone marrow-derived MSCs.", "population_specificity": "Patients with liver disease", "effective_dosage": "Not specified", "study_duration": "Up to 6 months follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:06.456574+00:00"}
{"study_id": 104075, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the epidemiological credibility of various risk factors, including increased levels of alanine aminotransferase, for type 2 diabetes mellitus (T2DM).", "results_summary": "The study found that increased levels of alanine aminotransferase were robustly associated with an elevated risk of T2DM, indicating a potential biomarker role in diabetes risk.", "population_specificity": "General population, focusing on risk factors for type 2 diabetes mellitus.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:08.015949+00:00"}
{"study_id": 104065, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the effects of rhGH treatment on cardiovascular risk factors, including alanine aminotransferase (ALT) levels, in obese children with relative growth hormone deficiency.", "results_summary": "RhGH treatment significantly reduced ALT levels (16.70\u2009\u00b1\u20096.72 vs. 45.20\u2009\u00b1\u200946.62\u00a0mmol/L, P\u2009=\u20090.002) compared to the control group, indicating improved liver enzyme profiles. The treatment also reduced BMI SDS, LDL-C, and AST while increasing HDL-C and IGF-1 levels.", "population_specificity": "Obese children with relative growth hormone deficiency (n=43).", "effective_dosage": "Not specified", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:09.376230+00:00"}
{"study_id": 104076, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to determine whether participating in a 161-km ultramarathon at altitude significantly increased traditional biomarkers of liver injury, including alanine aminotransferase (ALT).", "results_summary": "The study found significant elevations in ALT levels post-race (from 23 \u00b1 10 U/L to 117 \u00b1 106 U/L), correlating with creatine kinase (CK), a marker of muscle injury, but no clinical consequences were reported.", "population_specificity": "Ultramarathon runners participating in the Leadville 100 race.", "effective_dosage": "Not available", "study_duration": "Single race event (30-hour cutoff)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:11.789315+00:00"}
{"study_id": 104079, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were attempting to determine the genetic factors associated with sleep-disordered breathing (SDB) and obstructive sleep apnea (OSA), not Alanine.", "results_summary": "The study did not investigate Alanine; it focused on the heritability and genetic risk loci of OSA and SDB.", "population_specificity": "Japanese general population", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:12.487578+00:00"}
{"study_id": 104080, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine the effects of TA-65 (containing Alanine) on metabolic syndrome parameters, including dyslipidemias, hypertension, and oxidative stress.", "results_summary": "TA-65 supplementation improved HDL cholesterol, reduced body mass index, waist circumference, LDL/HDL ratio, and plasma TNF-\u03b1, with favorable changes in HDL associated with decreased inflammation.", "population_specificity": "40 patients with metabolic syndrome.", "effective_dosage": "16 mg daily.", "study_duration": "12 weeks per treatment phase, with a 3-week washout.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:14.615341+00:00"}
{"study_id": 104077, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers investigated the impact of anti-E1E2 seroprevalence at baseline on treatment response in patients receiving direct-acting antiviral (DAA) therapy, including the role of alanine aminotransferase (ALT) levels as a potential confounder.", "results_summary": "The presence of anti-E1E2 at baseline was significantly associated with sustained virological response (SVR) in DAA-treated patients, particularly those with low initial HCV viral load (<6log10). ALT levels were adjusted for in the multivariate analysis but were not a primary focus of the results.", "population_specificity": "Patients with hepatitis C virus (HCV) receiving DAA therapy, including both treatment-na\u00efve and experienced individuals.", "effective_dosage": "Not specified for alanine.", "study_duration": "Not specified for alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:14.651510+00:00"}
{"study_id": 104078, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to develop and validate a risk prediction model for MERS-CoV infection in pneumonia patients, including low alanine aminotransferase (ALT) as a predictive factor.", "results_summary": "The study found that low ALT levels, among other factors, were associated with an increased risk of MERS-CoV infection in pneumonia patients. The risk prediction model performed well with an AUC of 0.8162.", "population_specificity": "Patients with confirmed pneumonia evaluated for MERS-CoV infection in Saudi Arabia.", "effective_dosage": "Not available", "study_duration": "Retrospective study spanning from September 1, 2012 to June 1, 2016.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:14.669665+00:00"}
{"study_id": 104081, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to assess whether birth weight is associated with liver function, specifically alanine transaminase (ALT) levels, in a population with minimal socio-economic confounding.", "results_summary": "The study found no association between birth weight and ALT levels using instrumental variable analysis, but observational analysis showed a negative association between birth weight and ALT (-1.23 IU/L).", "population_specificity": "Adolescents (~17 years old) from the \"Children of 1997\" birth cohort (n = 8327).", "effective_dosage": "Not available", "study_duration": "Not applicable (observational study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:16.729858+00:00"}
{"study_id": 104082, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine the risk of hepatotoxicity, specifically elevations in alanine aminotransferase (ALT), associated with nivolumab therapy in cancer patients.", "results_summary": "The study found that nivolumab significantly increased the risk of ALT elevations, with incidences of 4.9% for all-grade and 1.7% for high-grade elevations. The relative risk for all-grade ALT elevation was 1.62 (95% CI 1.2-2.3).", "population_specificity": "Cancer patients enrolled in phase I-III clinical trials of nivolumab.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Combination with ipilimumab significantly increased the risk of ALT elevation.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:18.204672+00:00"}
{"study_id": 104084, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were attempting to determine whether thrombophilia worsens maternal and foetal outcomes, including liver function markers like alanine aminotransferase (ALT), in patients with severe preeclampsia.", "results_summary": "The study found that thrombophilia was associated with worsening maternal laboratory parameters, including elevated alanine aminotransferase (ALT \u2265 70 mg/dL), but did not worsen perinatal outcomes.", "population_specificity": "Pregnant women with severe preeclampsia diagnosed before 34 weeks of gestation.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:20.502169+00:00"}
{"study_id": 104083, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were assessing the safety and antitumour activity of the combination therapy of avelumab and axitinib in treatment-naive patients with advanced renal-cell carcinoma, not specifically focused on Alanine.", "results_summary": "The study reported that the combination therapy had a manageable safety profile and showed encouraging antitumour activity, with 58% of patients experiencing confirmed objective responses. Adverse events included increased concentrations of alanine aminotransferase in some patients.", "population_specificity": "Treatment-naive patients with advanced renal-cell carcinoma with clear-cell component.", "effective_dosage": "Avelumab 10 mg/kg every 2 weeks and axitinib 5 mg twice daily.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:21.235019+00:00"}
{"study_id": 104085, "supplement_id": 863, "safety_score": "100", "efficacy_score": 90, "quality_score": 85, "study_goal": "The researchers sought to determine if artichoke leaf extract (ALE) had therapeutic utility in patients with established non-alcoholic fatty liver disease (NAFLD).", "results_summary": "ALE supplementation significantly improved liver ultrasound parameters, reduced serum ALT and AST levels, improved AST/ALT ratio and APRI scores, and lowered lipid concentrations in NAFLD patients. No side effects were reported.", "population_specificity": "100 subjects with ultrasound-diagnosed NAFLD.", "effective_dosage": "600 mg daily", "study_duration": "2 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:21.748235+00:00"}
{"study_id": 104087, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the effectiveness, safety, and tolerability of the nutritional supplement Essential AD2 in reducing blood acetaldehyde levels in individuals with ALDH2 deficiency after alcohol consumption.", "results_summary": "The study found a significant decrease in blood acetaldehyde levels 20 minutes after alcohol consumption following 28 days of the supplement, with additional non-significant decreases at 10 and 40 minutes. Liver function tests also improved, and no significant side effects were reported.", "population_specificity": "12 subjects heterozygous for the ALDH2 gene mutation.", "effective_dosage": "Not specified.", "study_duration": "28 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:22.738574+00:00"}
{"study_id": 104086, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 85, "study_goal": "The researchers aimed to determine whether tenofovir disoproxil fumarate (TDF) could reduce mother-to-child HBV transmission in HBeAg-positive pregnant women with elevated HBV DNA levels.", "results_summary": "The study found that maternal use of TDF did not significantly lower the rate of HBV transmission to infants compared to placebo, despite the infants receiving hepatitis B immune globulin and vaccine. The transmission rate was low in both groups, suggesting limited additional benefit from TDF in this setting.", "population_specificity": "HBeAg-positive pregnant women with an alanine aminotransferase level \u226460 IU/L and elevated HBV DNA levels.", "effective_dosage": "Not specified (TDF or placebo from 28 weeks of gestation to 2 months postpartum).", "study_duration": "From 28 weeks of gestation to 2 months postpartum.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:24.903462+00:00"}
{"study_id": 104088, "supplement_id": 863, "safety_score": "30", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the liver safety profile of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in patients with type 2 diabetes mellitus.", "results_summary": "Fasiglifam showed an increased incidence of serum alanine aminotransferase (ALT) elevations compared to placebo and active comparators, with three serious liver injury cases attributed to its use, leading to the termination of its clinical development.", "population_specificity": "Patients with type 2 diabetes mellitus (n=9139).", "effective_dosage": "25 mg or 50 mg daily.", "study_duration": "Over 1 year for some patients.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:25.483605+00:00"}
{"study_id": 104089, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The study aimed to investigate the prevalence and risk factors of NAFLD, including the role of alanine aminotransferase, and assess the impact of community intervention on NAFLD patients.", "results_summary": "Alanine aminotransferase was identified as a risk factor for NAFLD. Community intervention significantly improved several health metrics, including BMI and blood pressure, in NAFLD patients.", "population_specificity": "Community residents in Urumqi, China (1000 participants, 344 men and 656 women, average age 51.79 years).", "effective_dosage": "Not specified", "study_duration": "8 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:26.561925+00:00"}
{"study_id": 104090, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effect of Agrimonia eupatoria L. aqueous extract (AEE) on reducing elevated alanine transaminase (ALT) levels in subjects with mild to moderately elevated ALT.", "results_summary": "The AEE group showed significant reductions in ALT and serum triglyceride levels compared to the placebo group, with no severe adverse events reported. Other liver function markers remained unchanged between groups.", "population_specificity": "Adults aged 20+ with mildly to moderately elevated ALT levels (45\u2013135 IU/L).", "effective_dosage": "Two capsules of AEE twice daily.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:28.590794+00:00"}
{"study_id": 104092, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the diagnosis, management, and fetal risks associated with intrahepatic cholestasis of pregnancy (ICP), including the role of alanine aminotransferase as a diagnostic marker.", "results_summary": "The study found that alanine aminotransferase levels are frequently elevated in ICP, but the focus was on bile acid levels and fetal risks rather than alanine's effects. No specific outcomes related to alanine supplementation or direct effects were discussed.", "population_specificity": "Pregnant women with intrahepatic cholestasis of pregnancy (ICP).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:30.346109+00:00"}
{"study_id": 104091, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and tolerability of prescription omega-3 fatty acid products (RxOME3FAs), including their effects on non-lipid laboratory measurements such as alanine transaminase.", "results_summary": "The study found that RxOME3FAs were associated with elevated alanine transaminase levels (p = 0.022), indicating a mild adverse effect on liver function, but no serious adverse events were definitively linked to RxOME3FAs.", "population_specificity": "24,460 participants across 21 randomized controlled trials (12,750 in RxOME3FA treatment cohort, 11,710 in control cohort).", "effective_dosage": "Not specified for alanine transaminase effects.", "study_duration": "Not specified for alanine transaminase effects.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:30.924706+00:00"}
{"study_id": 104093, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the efficacy and safety of adjuvant vemurafenib monotherapy in patients with resected BRAF V600-mutated melanoma, not specifically focused on Alanine.", "results_summary": "Elevated alanine aminotransferase (ALT) was reported as a grade 3-4 adverse event in 6% of patients receiving vemurafenib, but the study did not assess Alanine's effects or efficacy.", "population_specificity": "Adults (\u226518 years) with resected stage IIC-IIIA-IIIB or IIIC BRAF V600-mutated melanoma.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Median follow-up was 33.5 months (cohort 2) and 30.8 months (cohort 1).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:32.030077+00:00"}
{"study_id": 104094, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify the precise clinical features of autoimmune hepatitis (AIH) with acute presentation, including the role of alanine transaminase (ALT) as a diagnostic marker.", "results_summary": "The study found that AIH patients with acute presentation had a median ALT level of 776 U/L, but no significant differences in ALT levels were observed between genders or ANA-positive and ANA-negative patients. Fibrosis was more common in older patients, and elevated ALP and GGT levels were identified as independent risk factors for disease relapse.", "population_specificity": "86 AIH patients with acute presentation (75 female, 11 male), aged from adolescent to over 80 years, median age 55 years, from facilities across Japan.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:35.508350+00:00"}
{"study_id": 104095, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to document changes in liver function, specifically alanine transaminase (ALT) levels, in patients with Cushing's syndrome treated with ketoconazole.", "results_summary": "The study found mild, asymptomatic increases in liver enzymes, including ALT, with a small percentage of patients developing liver injury, primarily in the first month of treatment. Most abnormalities were reversible upon discontinuation of ketoconazole.", "population_specificity": "Patients with Cushing's syndrome (108 total: 47 KTZ-na\u00efve, 61 KTZ-switch).", "effective_dosage": "Median dose of 600 mg/day ketoconazole.", "study_duration": "Monitoring occurred at regular intervals, with liver injury primarily observed within the first month.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:36.183574+00:00"}
{"study_id": 104098, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were reviewing the pharmacology, pharmacokinetics, clinical efficacy, safety, and place in therapy of alectinib for non-small-cell lung cancer (NSCLC) patients.", "results_summary": "The abstract mentions that alectinib appears to be effective and safe for metastatic NSCLC patients, but no specific results about Alanine are provided.", "population_specificity": "Patients with non-small-cell lung cancer (NSCLC) driven by mutations.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:37.712527+00:00"}
{"study_id": 104097, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, pharmacokinetics, maximum tolerated dose, and preliminary efficacy of combining sorafenib and eribulin mesylate in patients with advanced tumors, including assessing dose-limiting toxicities such as increased alanine aminotransferase.", "results_summary": "The study found dose-limiting toxicities including increased alanine aminotransferase (grade 3) at the 400 mg BID sorafenib dose. No significant drug-drug interactions or QT/QTc interval impacts were observed. Partial responses and stable disease were achieved in some patients.", "population_specificity": "Patients with advanced, metastatic, or refractory tumors.", "effective_dosage": "Sorafenib at 200 mg BID, 600 mg/day, and 400 mg BID (MTD).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:38.290785+00:00"}
{"study_id": 104096, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 90, "study_goal": "The researchers aimed to determine the efficacy and safety of combining allopurinol with thiopurine in patients with IBD who exhibited thiopurine hypermethylation, and to compare two doses of allopurinol (50 mg/d vs. 100 mg/d).", "results_summary": "The study found that the allopurinol-thiopurine combination safely reversed thiopurine shunting and optimized 6TGN levels, leading to improved disease activity. Both doses of allopurinol were effective, but 100 mg/d was preferable due to greater metabolite stability and lower thiopurine dose requirements without additional toxicity.", "population_specificity": "Patients with clinically active or steroid-dependent IBD and thiopurine shunting.", "effective_dosage": "50 mg/d or 100 mg/d allopurinol, with 25% of the screening thiopurine dose (subsequently optimized).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:38.470595+00:00"}
{"study_id": 104099, "supplement_id": 863, "safety_score": "70", "efficacy_score": 65, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the safety and effects of statin prescription in patients with elevated alanine transaminase (ALT) levels (>3\u00d7 upper normal limit).", "results_summary": "Most patients showed improved or stable ALT levels after statin administration, with no significant differences between groups. Two subjects experienced temporary deterioration, but their ALT levels later stabilized.", "population_specificity": "Patients with baseline ALT levels >3\u00d7 the upper normal limit, divided into groups based on prior or concurrent use of liver-affecting agents (HEPA).", "effective_dosage": "Not specified", "study_duration": "3 months", "interactions": "Statins combined with liver-affecting agents (HEPA) were studied, but no harmful interactions were noted.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:40.584672+00:00"}
{"study_id": 104100, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the safety and efficacy of nivolumab treatment in Japanese patients with malignant melanoma, including monitoring adverse events such as abnormal enzyme activity (e.g., alanine aminotransferase).", "results_summary": "The study found that nivolumab treatment was associated with adverse drug reactions, including abnormal enzyme activity (e.g., alanine aminotransferase increase in 6.76% of patients). No new safety concerns were raised, and efficacy was observed in both cutaneous and mucosal melanoma patients.", "population_specificity": "Japanese patients with malignant melanoma.", "effective_dosage": "2 mg/kg every 3 weeks (intravenous infusion).", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:41.890096+00:00"}
{"study_id": 104101, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to determine the effects of intermittent whole-body hypoxic preconditioning on patients with carotid artery stenosis, including the impact on serum alanine aminotransferase levels.", "results_summary": "The study found no significant differences in serum alanine aminotransferase levels between preoperative and postoperative values in either the hypoxic intervention or control groups.", "population_specificity": "Fifty patients with carotid artery stenosis.", "effective_dosage": "Not specified for alanine.", "study_duration": "7 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:43.285045+00:00"}
{"study_id": 104102, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the laboratory and endometrial safety of topical testosterone versus topical estrogen for treating vaginal atrophy in postmenopausal women, not specifically Alanine.", "results_summary": "The study found no significant differences in hormonal or metabolic laboratory values, including alanine aminotransferase, among the treatment groups. No adverse effects related to Alanine were reported.", "population_specificity": "Postmenopausal women aged 40-70 years with symptoms of vaginal atrophy.", "effective_dosage": "Not applicable (study did not focus on Alanine supplementation).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:46.174779+00:00"}
{"study_id": 104103, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the impact of curcuminoids plus piperine on glycemic, hepatic, and inflammatory biomarkers, including alanine aminotransferase (ALT) levels, in type 2 diabetes patients.", "results_summary": "The study found a significant reduction in serum alanine aminotransferase (ALT) levels (-2\u00b16 vs. -1\u00b15; p=0.032) in the intervention group compared to placebo, indicating potential hepatic benefits. No significant changes in high-sensitivity C-reactive protein (hs-CRP) were observed.", "population_specificity": "Type 2 diabetes patients aged 18-65 years.", "effective_dosage": "500 mg/day curcuminoids co-administered with 5 mg/day piperine.", "study_duration": "3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:48.887738+00:00"}
{"study_id": 104105, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the benefits of antiviral therapy (interferon-\u03b1 and lamivudine) in children with immune-tolerant chronic hepatitis B infection, characterized by normal or mildly elevated alanine aminotransferase levels.", "results_summary": "The study found that sequential combination therapy of interferon-\u03b1 and lamivudine significantly improved rates of undetectable serum HBV DNA, HBeAg seroconversion, and HBsAg loss in children with immune-tolerant chronic HBV infection, compared to the control group. No serious adverse events were reported.", "population_specificity": "Chronically HBV-infected children aged 1 to 16 years with immune-tolerant characteristics (HBeAg positivity, high viral load, normal/mildly elevated alanine aminotransferase, minimal liver inflammation).", "effective_dosage": "Not specified (interferon-\u03b1 monotherapy, combination therapy with lamivudine, and lamivudine monotherapy were used sequentially).", "study_duration": "96 weeks (observation period).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:52.116628+00:00"}
{"study_id": 104106, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to compare the benefits and drawbacks of laparoscopic left lateral hepatic sectionectomy (LLLHS) versus open left lateral hepatic sectionectomy (OLLHS), including postoperative alanine aminotransferase levels.", "results_summary": "The study found no significant differences in postoperative alanine aminotransferase levels between LLLHS and OLLHS (P = .57). LLLHS showed advantages in blood transfusion, blood loss, total morbidity, and hospital stay compared to OLLHS.", "population_specificity": "Patients undergoing left lateral hepatic sectionectomy (segments II/III).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:52.436447+00:00"}
{"study_id": 104107, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the long-term efficacy of entecavir (ETV) and lamivudine (LAM) therapy in children with chronic hepatitis B (CHB), focusing on virologic suppression, ALT normalization, and HBeAg seroconversion.", "results_summary": "ETV showed higher virologic suppression rates (91.7% at 3 years) and lower rates of virologic breakthrough and genotypic mutation compared to LAM, though HBeAg seroconversion rates were similar between the groups.", "population_specificity": "Pediatric CHB patients younger than 20 years with no prior nucleoside analogue treatment or concomitant diseases.", "effective_dosage": "Not specified", "study_duration": "At least 12 months (follow-up up to 6 years)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:53.651046+00:00"}
{"study_id": 104104, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 45, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of sequential therapy with adefovir (ADV) or entecavir (ETV) followed by peginterferon alfa-2a versus peginterferon alfa-2a monotherapy in Taiwanese patients with HBeAg-positive chronic hepatitis B.", "results_summary": "The study found no significant differences in HBeAg seroconversion, HBeAg loss, or HBsAg level changes among the treatment groups. However, hepatitis B virus DNA levels were higher with peginterferon alfa-2a monotherapy compared to combination therapy at certain time points, and ALT normalization rates varied between groups.", "population_specificity": "Taiwanese patients with HBeAg-positive chronic hepatitis B (N = 280).", "effective_dosage": "Not specified for alanine (study focused on ADV, ETV, and PEG-IFN alfa-2a).", "study_duration": "48 weeks (4 weeks of monotherapy, 2 weeks of combination therapy, followed by 46 weeks of PEG-IFN alfa-2a alone).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:53.825005+00:00"}
{"study_id": 104109, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers sought to determine whether delayed elevation in liver transaminases (a component of LFTs) occurs after naturally acquired malaria infection, similar to what was observed in induced blood stage malaria infection.", "results_summary": "The abstract does not provide specific results regarding Alanine's effects, as it focuses on liver function test elevations in malaria cases.", "population_specificity": "Confirmed cases of naturally acquired malaria infection.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:54.189532+00:00"}
{"study_id": 104108, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and antitumour activity of combining axitinib (a VEGF inhibitor) with pembrolizumab (anti-PD-1) in patients with treatment-naive advanced renal cell carcinoma, not specifically focusing on Alanine.", "results_summary": "The study found that the combination of axitinib and pembrolizumab was tolerable and showed promising antitumour activity, with 73% of patients achieving an objective response. Increased alanine aminotransferase concentration was noted as a common adverse event, but the study did not focus on Alanine's effects.", "population_specificity": "Patients aged 18+ with advanced renal cell carcinoma (predominantly clear cell subtype), primary tumour resected, and no previous systemic therapy.", "effective_dosage": "Axitinib 5 mg orally twice daily; pembrolizumab 2 mg/kg intravenously every 3 weeks.", "study_duration": "Ongoing study with data cutoff at March 31, 2017 (enrollment from 2014-2015).", "interactions": "None mentioned regarding Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:56.673842+00:00"}
{"study_id": 104110, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate whether a modified bi-weekly eribulin schedule is safe and effective for patients with metastatic breast cancer intolerant to the standard eribulin dose and schedule.", "results_summary": "The study found that bi-weekly eribulin therapy had comparable efficacy to standard therapy, with similar clinical benefit rates and overall survival, and no severe adverse events reported in either group.", "population_specificity": "Patients with metastatic breast cancer previously treated with anthracycline and taxane, and \u22643 prior chemotherapy regimens.", "effective_dosage": "Standard dose (1.4 mg/m\u00b2) and modified bi-weekly schedule.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:40:57.154157+00:00"}
{"study_id": 104111, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the role of alanine aminotransferase (ALT) levels in guiding treatment strategies for chronic hepatitis B (CHB) patients, particularly in optimizing the cost-effectiveness of Peg-IFN therapy.", "results_summary": "The study found that baseline ALT levels, along with other factors like HBV DNA levels and viral genotype, are critical for selecting CHB patients who may benefit most from Peg-IFN therapy. Early on-treatment stopping rules based on HBsAg kinetics can enhance the cost-effectiveness of Peg-IFN.", "population_specificity": "Chronic hepatitis B (CHB) patients", "effective_dosage": "Not specified", "study_duration": "Long-term follow-up (specific duration not mentioned)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:00.223282+00:00"}
{"study_id": 104113, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the association between ALT flares and HBsAg loss during long-term nucleos(t)ide analogue therapy in genotype A chronic hepatitis B patients.", "results_summary": "The study found that 43% of subjects experienced ALT flares during therapy, and 45% achieved significant HBsAg reduction. ALT flares were predictive of HBsAg response, suggesting implications for immunomodulatory therapy trial design.", "population_specificity": "Genotype A subjects with HBeAg-positive chronic hepatitis B from a phase III study.", "effective_dosage": "Not specified", "study_duration": "384 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:00.237204+00:00"}
{"study_id": 104112, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the effects of stopping tenofovir treatment in HBeAg-negative chronic hepatitis B patients and whether this could trigger immune control leading to HBsAg loss or sustained low HBV DNA levels.", "results_summary": "The study found that most patients did not require retreatment after stopping tenofovir, despite transient HBV DNA relapse, and nearly 20% achieved HBsAg loss approximately 3 years post-cessation. The findings suggest that finite therapy may be viable for certain patients without severe conditions, provided safety rules for retreatment are followed.", "population_specificity": "HBeAg-negative chronic hepatitis B patients without cirrhosis or other severe conditions.", "effective_dosage": "Not specified", "study_duration": "Nearly 3 years post-cessation", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:01.562966+00:00"}
{"study_id": 104114, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 90, "study_goal": "The researchers aimed to determine the most suitable therapeutic dose of condoliase for treating lumbar disc herniation (LDH) by evaluating its efficacy and safety.", "results_summary": "Condoliase significantly improved leg pain and other clinical symptoms in LDH patients compared to placebo, with sustained effects observed up to week 52. Safety profiles were favorable, though dose-dependent adverse reactions and disc height reduction were noted.", "population_specificity": "Patients aged 20-70 with unilateral leg pain, positive straight leg raise test, and lumbar disc herniation.", "effective_dosage": "1.25 U, 2.5 U, or 5 U (single injection).", "study_duration": "Follow-up until week 52.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:02.504699+00:00"}
{"study_id": 104115, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate hepatobiliary system involvement in paracoccidioidomycosis (PCM) patients and the effects of antifungal treatments (cotrimoxazole or itraconazole) on this system, including monitoring serum levels of alanine aminotransferase (ALT).", "results_summary": "The study found elevated ALT levels in PCM patients at admission (32.6% for GGT, ALT not specified). After treatment, elevated ALT levels persisted in 27.5% of cases, particularly in itraconazole-treated patients, though therapy was not discontinued.", "population_specificity": "200 paracoccidioidomycosis (PCM) patients (51 acute/subacute form, 149 chronic form).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:02.745804+00:00"}
{"study_id": 104116, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine risk factors for hepatotoxicity in severely immunosuppressed individuals taking isoniazid preventive therapy (IPT) and antiretroviral therapy (ART), with a focus on elevated alanine aminotransferase (ALT) levels.", "results_summary": "The study found that raised pretreatment AST/ALT levels and HBsAg seropositivity were significantly associated with an increased risk of hepatotoxicity, with the highest risk observed in participants with both conditions. The incidence of hepatotoxicity was 7.3% among the study population.", "population_specificity": "Severely immunosuppressed individuals with HIV (pre-ART CD4 cell counts <50 cells/\u03bcL) in resource-limited settings with a high burden of tuberculosis.", "effective_dosage": "Not specified", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:04.196050+00:00"}
{"study_id": 104117, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to explore and contrast the phenotypes associated with higher ALT (alanine aminotransferase) and high-risk NAFLD fibrosis score (NFS) in type 2 diabetes.", "results_summary": "Higher ALT was associated with lower rates of osteoporosis/osteopenia and inability to sense the monofilament, while high-risk NFS was linked to arrhythmia, elevated VPT, and albuminuria. The associations of high-risk NFS with albuminuria and elevated VPT remained significant after adjustment.", "population_specificity": "324 patients with type 2 diabetes mellitus seen at a diabetes center for complications assessment.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:04.977114+00:00"}
{"study_id": 104118, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to assess the activity of pembrolizumab in patients with advanced thymic carcinoma, not specifically Alanine.", "results_summary": "The study found that pembrolizumab showed a response rate of 22.5% in thymic carcinoma patients, with some severe autoimmune toxicities noted. Alanine aminotransferase elevation was reported as an adverse event in 13% of patients.", "population_specificity": "Patients with recurrent thymic carcinoma who had progressed after at least one line of chemotherapy.", "effective_dosage": "Not applicable (study focused on pembrolizumab, not Alanine).", "study_duration": "Up to 2 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:05.486501+00:00"}
{"study_id": 104119, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate a new model for assessing malaria transmission from humans to mosquitoes, focusing on gametocyte development and transmission-blocking interventions, not specifically on Alanine.", "results_summary": "The study found elevated alanine aminotransferase levels as a transient, asymptomatic adverse event attributed to malaria infection, but did not assess Alanine's effects or efficacy.", "population_specificity": "Healthy malaria-naive volunteers", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:07.201836+00:00"}
{"study_id": 104120, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the role of alanine aminotransferase (ALT) levels in confounding liver stiffness measurements (LSM) for assessing liver fibrosis and its regression.", "results_summary": "The study found that ALT levels can confound LSM results, making it less accurate for indicating liver fibrosis regression. Combining LSM with ALT-independent serum-based formulas (e.g., Forns index) may improve accuracy.", "population_specificity": "Patients with chronic liver diseases, particularly chronic hepatitis B.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:07.916821+00:00"}
{"study_id": 104121, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not investigate Alanine; it focuses on the efficacy and safety of nivolumab alone or in combination with ipilimumab for treating metastatic sarcoma.", "results_summary": "The study does not report any findings related to Alanine.", "population_specificity": "Patients with locally advanced, unresectable, or metastatic sarcoma.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:08.938249+00:00"}
{"study_id": 104122, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy and safety of different antiviral therapies, including combinations involving lamivudine and adefovir dipivoxil, as well as entecavir monotherapy, in patients with hepatitis B-induced decompensated cirrhosis, with a focus on alanine aminotransferase (ALT) levels.", "results_summary": "The study found that combination therapy and early ADV addition significantly improved ALT levels, albumin, and total bilirubin, while the 24-week optimized therapy group showed improvement only in ALT levels. No significant differences were observed in ALT normalization, HBV DNA negative conversion, or HBeAg seroconversion among the combination therapy, 12-week optimized therapy, and ETV monotherapy groups.", "population_specificity": "Patients with hepatitis B-induced decompensated cirrhosis (n=127).", "effective_dosage": "Not specified in the abstract.", "study_duration": "96 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:13.093192+00:00"}
{"study_id": 104124, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify the prevalence of lysosomal acid lipase deficiency (LALD) in patients with dyslipidaemia and elevated transaminases, including alanine transaminase.", "results_summary": "The study screened 1825 patients with dyslipidaemia and elevated transaminases but found no cases of LALD. Two patients were homozygous for an unclassified LAL gene variant, but no direct effects of alanine were reported.", "population_specificity": "Patients with dyslipidaemia and elevated alanine or aspartate transaminases (\u226560 IU/L).", "effective_dosage": "Not available", "study_duration": "Data collected over a 3-year interval.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:13.266047+00:00"}
{"study_id": 104123, "supplement_id": 863, "safety_score": "60", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of E7777 (a fusion protein containing alanine-related components) in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma.", "results_summary": "E7777 showed dose-limiting toxicities at higher doses (12 \u03bcg/kg/day) but was well-tolerated at 9 \u03bcg/kg/day, with an objective response rate of 38%. Preliminary antitumor activity was observed, though efficacy did not correlate with CD25 expression.", "population_specificity": "Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma (n=13).", "effective_dosage": "6, 9, and 12 \u03bcg/kg/day via i.v. infusion for five consecutive days per 21-day cycle.", "study_duration": "Five consecutive days per 21-day cycle (specific total duration not detailed).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:13.514677+00:00"}
{"study_id": 104125, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of implementing pediatric overweight/obesity recommendations, including assessing metabolic parameters such as alanine transaminase levels.", "results_summary": "The study found that the Standard Care + Enhanced Program significantly improved alanine transaminase concentrations compared to Standard Care Alone, suggesting a positive metabolic effect. Both interventions led to modest declines in BMI Z-scores, but the enhanced program showed additional benefits in metabolic markers.", "population_specificity": "Children aged 7-12 years with BMI \u226585th percentile (74% Hispanic/Latino) in a safety-net pediatric primary care setting.", "effective_dosage": "Not specified", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:13.741084+00:00"}
{"study_id": 104126, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the immune-tolerant phase of chronic hepatitis B (CHB) and the role of alanine aminotransferase (ALT) levels in defining this phase.", "results_summary": "The study highlights the complexity of CHB's immune phases, noting that the immune-tolerant phase is not well understood and lacks consensus in guidelines. It suggests that treating immune-tolerant CHB patients may reduce liver fibrosis and hepatocellular carcinoma risk, but current guidelines advise against antiviral treatment for this group.", "population_specificity": "Patients with chronic hepatitis B (CHB), particularly those in the immune-tolerant phase.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:14.322115+00:00"}
{"study_id": 104128, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of EPA-PL and DHA-PL on NAFLD, including their impact on alanine aminotransferase (ALT) levels.", "results_summary": "Lipo-EPA significantly reduced orotic acid-induced ALT levels by 34.2% (p < 0.01), indicating improved hepatic function. EPA-PL and lipo-DHA also suppressed hepatic lipid accumulation by enhancing lipolysis and cholesterol efflux.", "population_specificity": "Not specified (likely animal or in vitro model based on the abstract).", "effective_dosage": "1% of total diets for EPA-PL and DHA-PL.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:16.940625+00:00"}
{"study_id": 104129, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the relationship between arginine-levodopa-induced growth hormone secretion and nonalcoholic fatty liver disease (NAFLD) in obese children, indirectly assessing associations involving alanine aminotransferase.", "results_summary": "The study found that peak stimulated GH was negatively associated with alanine aminotransferase (ALT) levels in obese children, suggesting a potential link between GH response and liver health. Lower GH and IGF-1 levels were also significantly associated with NAFLD presence.", "population_specificity": "84 obese children and adolescents (with and without NAFLD) and 43 normal-weight controls.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:19.366322+00:00"}
{"study_id": 104133, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not focus on Alanine; it investigates a combination therapy for HER2-positive, ER-positive breast cancer.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Patients with HER2-positive, ER-positive breast cancer.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:20.133314+00:00"}
{"study_id": 104131, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to determine the influence of obstructive sleep apnea (OSA) on alanine transaminase (ALT) levels and its association with non-alcoholic fatty liver disease (NAFLD) histological lesions.", "results_summary": "The study found that OSA was related to ALT levels but not aspartate transaminase (AST) levels. OSA severity was associated with ALT levels and correlated with steatosis, lobular inflammation, ballooning degeneration, and fibrosis, but not with NAFLD activity score (NAS).", "population_specificity": "2,272 participants with OSA and NAFLD from studies reviewed between 2007 and 2017.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:21.949274+00:00"}
